<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">84235</article-id><article-id pub-id-type="doi">10.7554/eLife.84235</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group></article-categories><title-group><article-title>A human mitofusin 2 mutation can cause mitophagic cardiomyopathy</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-198508"><name><surname>Franco</surname><given-names>Antonietta</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5487-1800</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-104468"><name><surname>Li</surname><given-names>Jiajia</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-282635"><name><surname>Kelly</surname><given-names>Daniel P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299076"><name><surname>Hershberger</surname><given-names>Ray E</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5683-6526</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299077"><name><surname>Marian</surname><given-names>Ali J</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299078"><name><surname>Lewis</surname><given-names>Renate M</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299079"><name><surname>Song</surname><given-names>Moshi</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299080"><name><surname>Dang</surname><given-names>Xiawei</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-0343-7107</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299081"><name><surname>Schmidt</surname><given-names>Alina D</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299082"><name><surname>Mathyer</surname><given-names>Mary E</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-117663"><name><surname>Edwards</surname><given-names>John R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-299083"><name><surname>Strong</surname><given-names>Cristina de Guzman</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-197979"><name><surname>Dorn</surname><given-names>Gerald W</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8995-1624</contrib-id><email>gdorn@wustl.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Internal Medicine, Pharmacogenomics, Washington University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">St Louis</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00b30xv10</institution-id><institution>Department of Medicine, Cardiovascular Institute, Perelman School of Medicine, University of Pennsylvania</institution></institution-wrap><addr-line><named-content content-type="city">Philadelphia</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/00rs6vg23</institution-id><institution>Department of Internal Medicine, Divisions of Human Genetics and Cardiovascular Medicine, Ohio State University</institution></institution-wrap><addr-line><named-content content-type="city">Columbus</named-content></addr-line><country>United States</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03gds6c39</institution-id><institution>Center for Cardiovascular Genetic Research, University of Texas Health Science Center at Houston</institution></institution-wrap><addr-line><named-content content-type="city">Houston</named-content></addr-line><country>United States</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Neurology, Washington University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01yc7t268</institution-id><institution>Department of Internal Medicine (Dermatology), Washington University School of Medicine</institution></institution-wrap><addr-line><named-content content-type="city">St. Louis</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chacinska</surname><given-names>Agnieszka</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01dr6c206</institution-id><institution>IMol Polish Academy of Sciences</institution></institution-wrap><country>Poland</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Pollak</surname><given-names>Martin R</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>01</day><month>11</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>12</volume><elocation-id>e84235</elocation-id><history><date date-type="received" iso-8601-date="2022-10-16"><day>16</day><month>10</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2023-09-26"><day>26</day><month>09</month><year>2023</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2022-11-23"><day>23</day><month>11</month><year>2022</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2022.11.22.517462"/></event></pub-history><permissions><copyright-statement>© 2023, Franco et al</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Franco et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-84235-v1.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-84235-figures-v1.pdf"/><abstract><p>Cardiac muscle has the highest mitochondrial density of any human tissue, but mitochondrial dysfunction is not a recognized cause of isolated cardiomyopathy. Here, we determined that the rare mitofusin (MFN) 2 R400Q mutation is 15–20× over-represented in clinical cardiomyopathy, whereas this specific mutation is not reported as a cause of MFN2 mutant-induced peripheral neuropathy, Charcot–Marie–Tooth disease type 2A (CMT2A). Accordingly, we interrogated the enzymatic, biophysical, and functional characteristics of MFN2 Q400 versus wild-type and CMT2A-causing MFN2 mutants. All MFN2 mutants had impaired mitochondrial fusion, the canonical MFN2 function. Compared to MFN2 T105M that lacked catalytic GTPase activity and exhibited normal activation-induced changes in conformation, MFN2 R400Q and M376A had normal GTPase activity with impaired conformational shifting. MFN2 R400Q did not suppress mitochondrial motility, provoke mitochondrial depolarization, or dominantly suppress mitochondrial respiration like MFN2 T105M. By contrast to MFN2 T105M and M376A, MFN2 R400Q was uniquely defective in recruiting Parkin to mitochondria. CRISPR editing of the R400Q mutation into the mouse <italic>Mfn2</italic> gene induced perinatal cardiomyopathy with no other organ involvement; knock-in of Mfn2 T105M or M376V did not affect the heart. RNA sequencing and metabolomics of cardiomyopathic Mfn2 Q/Q400 hearts revealed signature abnormalities recapitulating experimental mitophagic cardiomyopathy. Indeed, cultured cardiomyoblasts and in vivo cardiomyocytes expressing MFN2 Q400 had mitophagy defects with increased sensitivity to doxorubicin. MFN2 R400Q is the first known natural mitophagy-defective MFN2 mutant. Its unique profile of dysfunction evokes mitophagic cardiomyopathy, suggesting a mechanism for enrichment in clinical cardiomyopathy.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Mitochondria are organelles with an essential role in providing energy to the cells of the body. If damaged, they are repaired by fusing and exchanging contents with sister mitochondria in a process that requires mitofusin proteins.</p><p>While mutations in the gene for mitofusin 2 have been linked to nerve damage, they do not appear to affect the heart – despite high concentrations of mitochondria in heart muscle cells. However, previous research showed that experimentally disrupting the programmed removal of mitochondria, a process also regulated by mitofusin 2, can cause heart muscle disease known as cardiomyopathy. This suggests that mutations affecting different mitofusin 2 roles might harm individual cell types in different ways.</p><p>To investigate, Franco et al. carried out a genetic screen of people with cardiomyopathy, identifying a rare mitofusin 2 mutation, called R400Q, that was more common in this group. Experiments showed that R400Q caused cardiomyopathy in mice and affected mitochondrial repair and replacement, but not movement. By contrast, a mutation linked to Charcot-Marie-Tooth disease type 2A – which causes nerve damage – affected mitochondrial movement but not clearance, leading to nerve cell damage but not cardiomyopathy. This led Franco et al. to suggest that mitochondrial movement is central to nerve cell health, whereas mitochondrial repair and replacement plays an important role in cardiac development.</p><p>Genetic cardiomyopathies affect around 1 in 500 people, but only half of the gene mutations responsible are known. These results suggest that mutations affecting mitochondrial quality control factors could be involved, highlighting a direction for future studies into modifiers of cardiomyopathy.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>cardiomyopathy</kwd><kwd>heart</kwd><kwd>mitochondria</kwd><kwd>mitofusins</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>NIH R35 HL135736</award-id><principal-award-recipient><name><surname>Dorn</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R42 NS113642</award-id><principal-award-recipient><name><surname>Dorn</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R42 NS115184</award-id><principal-award-recipient><name><surname>Dorn</surname><given-names>Gerald W</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R01 HL128349</award-id><principal-award-recipient><name><surname>Kelly</surname><given-names>Daniel P</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>A rare human mitofusin (MFN) 2 mutation that uniquely impaired Parkin-mediated mitophagy evoked developmental heart disease and increased myocardial sensitivity to doxorubicin in mice, differentiating it from mitophagy-competent MFN2 mutations that cause neuropathy and implicating mitophagy in clinical cardiomyopathy.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Hearts rely upon mitochondria-derived ATP to fuel cardiac development, excitation–contraction–coupling, and myocardial repair after damage or senescence. For this reason, cardiac involvement is common in diseases like MELAS and MERRF caused by genetic defects of the mitochondrial genome (mtDNA) (<xref ref-type="bibr" rid="bib27">Hsu et al., 2016</xref>). However, the vast majority of the ~1000 constituent mitochondrial proteins are not encoded by mtDNA, but instead by nuclear genes. Among nuclear-encoded mitochondrial proteins having central roles in mitochondrial health and homeostasis are mitofusins (MFN) 1 and 2 (<xref ref-type="bibr" rid="bib47">Santel and Fuller, 2001</xref>). Gene ablation and mutant transgene expression studies targeting cardiac myocytes indicate that cardiac MFNs are critical mediators of reparative mitochondrial fusion (<xref ref-type="bibr" rid="bib9">Chen et al., 2011</xref>; <xref ref-type="bibr" rid="bib30">Kasahara et al., 2013</xref>), mitochondrial culling for quality control (<xref ref-type="bibr" rid="bib49">Song et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Song et al., 2017</xref>), and mitochondrial replacement for metabolic plasticity (<xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>).</p><p>Clinical and experimental data relating MFN functioning to cardiac health appear somewhat discordant. On the one hand, the cited <italic>Mfn</italic> gene knockout studies unambiguously demonstrate that mitofusins are essential for heart development, contraction, and repair. On the other hand, cardiac involvement has not been reported in human conditions caused by natural loss-of-function <italic>MFN</italic> gene mutations. Indeed, dozens of different pathological <italic>MFN2</italic> mutations cause neuronal rather than cardiac pathology, manifested as Charcot–Marie–Tooth disease type 2A (CMT2A) (<xref ref-type="bibr" rid="bib58">Züchner et al., 2004</xref>) or optic degeneration (<xref ref-type="bibr" rid="bib59">Züchner et al., 2006</xref>). We have proposed that mitochondrial motility defects induced by mutant MFN2 are responsible for clinical neuropathies because neurons have long axonal and dendritic processes that make them critically dependent upon mitochondrial transport (<xref ref-type="bibr" rid="bib16">Dorn, 2019</xref>; <xref ref-type="bibr" rid="bib18">Dorn, 2021</xref>). By contrast, impaired mitophagy seems to underlie developmental and senescent cardiomyopathies provoked by <italic>Mfn</italic> gene ablation or engineered MFN2 mutant expression (<xref ref-type="bibr" rid="bib3">Bhandari et al., 2014</xref>; <xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>; <xref ref-type="bibr" rid="bib15">Dorn, 2016</xref>).</p><p>MFN2 multifunctionality reflects its ability to bind different protein partners as determined by specific phosphorylation events (<xref ref-type="bibr" rid="bib17">Dorn, 2020</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>). Thus, MFN2 oligomerization with MFN1 or MFN2 mediates mitochondrial fusion (<xref ref-type="bibr" rid="bib8">Chen et al., 2010</xref>; <xref ref-type="bibr" rid="bib19">Dorn and Dang, 2022</xref>), MFN2 binding of Parkin mediates mitophagy (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>), and MFN2 binding to Miro regulates mitochondrial transport (<xref ref-type="bibr" rid="bib41">Misko et al., 2010</xref>). We reasoned that mutations affecting different MFN2 domains could evoke a phenotypic spectrum consisting of mitochondrial fragmentation from loss of fusion, mitochondrial dysmotility from impaired transport, and/or mitochondrial degeneration from interrupted mitophagy.</p><p>Here, as part of an ongoing effort to understand the relationship between <italic>MFN2</italic> mutation site, protein dysfunction, and disease manifestation, we screened cardiomyopathy research cohorts for MFN2 mutations linked to cardiac hypertrophy or heart failure. A largely overlooked, very rare <italic>MFN2</italic> mutation, MFN2 R400Q (<xref ref-type="bibr" rid="bib20">Eschenbacher et al., 2012</xref>), was over-represented in cardiomyopathy among individuals of African descent. We found that fusogenicity of mutant MFN2 Q400 is depressed to the same extent as CMT2A mutants MFN2 T105M and M376 A/V. Uniquely, MFN2 Q400 is defective in recruiting Parkin to mitochondria, thereby impacting an important mitophagic pathway. Knockin (KI) mice engineered to carry Mfn2 Q400 develop a perinatal cardiomyopathy, whereas Mfn2 T105M KI mice develop a CMT2A-like neuropathy and Mfn2 M376V KI mice appear phenotypically normal. To our knowledge, MFN2 R400Q is the first example of a naturally occurring <italic>MFN2</italic> mutation that primarily impacts mitophagy. These findings designate mitophagic dysfunction as a new mechanism for cardiomyopathy, supporting targeted investigations of other genetic mitophagy defects as cardiac risk modifiers. Finally, our data support the concept that different patterns of mitofusin dysfunction underlie organ-specific manifestations of clinical diseases caused by <italic>MFN2</italic> mutations.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>The rare MFN2 R400Q mutation is over-represented in clinical cardiomyopathy</title><p>Rare mutations can be overlooked in standard genotype–phenotype association studies, requiring targeted analyses of exome/whole-genome sequence data (<xref ref-type="bibr" rid="bib2">Auer and Lettre, 2015</xref>; <xref ref-type="bibr" rid="bib4">Bomba et al., 2017</xref>). Here, to define the landscape of potential disease-causing <italic>MFN2</italic> variants (<xref ref-type="bibr" rid="bib37">MacArthur et al., 2012</xref>) we surveyed the gnomAD database (v2.1.1) of 141,456 individuals for rare (minor allele frequency [MAF] of 0.001–0.01) nonsynonymous MFN2 sequence variants. A total of 352 rare nonsynonymous <italic>MFN2</italic> variants are reported (MAF 3.98E-06–6.87 E-03) of which 171 are singletons. Notably, 76 of the rare <italic>MFN2</italic> variants are implicated in CMT2A (<xref ref-type="bibr" rid="bib52">Stuppia et al., 2015</xref>; <xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>).</p><p>To detect any <italic>MFN2</italic> variants associated with human heart conditions, <italic>MFN2</italic> gene exons were resequenced in DNA samples from 398 subjects with idiopathic/non-ischemic dilated cardiomyopathy (DCM) from the Cincinnati Heart Study (<xref ref-type="bibr" rid="bib35">Liggett et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Matkovich et al., 2010</xref>; <xref ref-type="bibr" rid="bib5">Cappola et al., 2011</xref>), 286 subjects with hypertrophic cardiomyopathy (HCM) from the Houston Hypertrophic Cardiomyopathy cohort (<xref ref-type="bibr" rid="bib44">Osio et al., 2007</xref>; <xref ref-type="bibr" rid="bib32">Li et al., 2017</xref>), and 861 non-affected controls from the Cincinnati cohort. Additionally, 424 individuals (281 probands) with familial cardiomyopathy (FCM) from the DCM Precision Medicine Study (<xref ref-type="bibr" rid="bib28">Huggins et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Trachtenberg et al., 2022</xref>) were screened. As summarized in <xref ref-type="table" rid="table1">Table 1</xref>, 11 non-synonymous <italic>MFN2</italic> variants were detected, 6 of which encode putative CMT2A mutations. Also, 8 of the 11 <italic>MFN2</italic> variants were singletons and therefore of minimal interest. MFN2 R400Q, which is not a known CMT2A mutation and is bioinformatically predicted to be damaging, was detected in three unrelated individuals: two with HCM and one with DCM (<xref ref-type="table" rid="table1">Table 1</xref>).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Results of genetic screening for MFN2 mutations in adult cardiomyopathy.</title><p>HCM, hypertrophic cardiomyopathy; DCM, dilated cardiomyopathy; MAF, minor allele frequency. MFN2 protein domains correspond to colored regions in <xref ref-type="fig" rid="fig1">Figure 1A</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">MFN2 variant</th><th align="left" valign="bottom">MFN2 domain</th><th align="left" valign="bottom">Polyphen 2</th><th align="left" valign="bottom">ClinVar</th><th align="left" valign="bottom">HCM n = 286</th><th align="left" valign="bottom">DCM1 n = 398</th><th align="left" valign="bottom">DCM2 n = 281 probands (424 cases)</th><th align="left" valign="bottom">CM MAF n = 965</th><th align="left" valign="bottom">gnomAD MAF n = 141,456</th><th align="left" valign="bottom">MAF CM vs. gnomAD (p-value)</th><th align="left" valign="bottom">MAF CM vs. gnomAD (X<sup>2</sup> stat)</th></tr></thead><tbody><tr><td align="left" valign="bottom">S180R</td><td align="left" valign="bottom">GTPase</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">CMT2A</td><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">1.591 E-05</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">V181M</td><td align="left" valign="bottom">GTPase</td><td align="left" valign="bottom">Prob dam</td><td align="left" valign="bottom">CMT2A</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1 family; 5 indiv</td><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">3.976 E-06</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">S263Y</td><td align="left" valign="bottom">GTPase</td><td align="left" valign="bottom">Pos dam</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Singleton</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td><td align="left" valign="bottom">-</td></tr><tr><td align="left" valign="bottom">R274Q</td><td align="left" valign="bottom">GTPase</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">CMT2A</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1 family; 4 indiv</td><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">2.486 E-05</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">G298R</td><td align="left" valign="bottom">GTPase</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">CMT2A</td><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">2.147 E-03</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">M393I</td><td align="left" valign="bottom">HR1</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">Likely benign</td><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">1.591 E-05</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R400Q</td><td align="left" valign="bottom">HR1</td><td align="left" valign="bottom">Prob dam</td><td align="left" valign="bottom">Uncertain significance</td><td align="char" char="." valign="bottom">2 hets</td><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="char" char="." valign="bottom">1.55 E-03</td><td align="char" char="." valign="bottom">7.423 E-05</td><td align="char" char="." valign="bottom">&lt;0.00001</td><td align="char" char="." valign="bottom">89.595</td></tr><tr><td align="left" valign="bottom">Q413P</td><td align="left" valign="bottom">HR1</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1 family; 1 indiv</td><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">1.193 E-05</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">R468H</td><td align="left" valign="bottom">inter</td><td align="left" valign="bottom">Pos dam</td><td align="left" valign="bottom">CMT2A</td><td align="char" char="." valign="bottom">1 het</td><td align="left" valign="bottom"/><td align="left" valign="bottom">2 families; 5 indiv</td><td align="char" char="." valign="bottom">1.55 E-03</td><td align="char" char="." valign="bottom">2.177 E-03</td><td align="left" valign="bottom">NS</td><td align="char" char="." valign="bottom">0.3431</td></tr><tr><td align="left" valign="bottom">V705I</td><td align="left" valign="bottom">HR2</td><td align="left" valign="bottom">Benign</td><td align="left" valign="bottom">Likely benign</td><td align="char" char="." valign="bottom">2 hets</td><td align="left" valign="bottom"/><td align="left" valign="bottom">6 families; 15 indiv</td><td align="char" char="." valign="bottom">4.14 E-03</td><td align="char" char="." valign="bottom">6.865 E-03</td><td align="left" valign="bottom">NS</td><td align="char" char="." valign="bottom">2.0848</td></tr><tr><td align="left" valign="bottom">A716T</td><td align="left" valign="bottom">HR2</td><td align="left" valign="bottom">Pos dam</td><td align="left" valign="bottom">CMT2A</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/><td align="left" valign="bottom">1 family; 1 indiv</td><td align="left" valign="bottom">Singleton</td><td align="char" char="." valign="bottom">1.308 E-04</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><p>The MFN2 R400Q mutation (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>) is reported almost exclusively in African populations in the gnomAD database (<xref ref-type="supplementary-material" rid="fig1sdata1">Figure 1—source data 1</xref>). Indeed, all three subjects with the R400Q variant in our cardiomyopathy study populations identified as African American. The overall <italic>MFN2</italic> R400Q MAF of 0.0015 in cardiomyopathy, when compared to MAF of 0.000074 from the gnomAD database, represents ~20-fold over-representation in the combined heart disease populations (p&lt;0.00001). If only the gnomAD African-derived population is used to account for racial differences in R400Q prevalence (10/24,962), over-representation was ~15-fold (p-value = 0.0033). None of the non-affected controls (625 Caucasian and 236 African American subjects) had the MFN2 R400Q mutation. Because a previous description of this <italic>MFN2</italic> mutant described impaired fusogenicity conferring retinal and myocardial abnormalities in transgenic <italic>Drosophila</italic> (<xref ref-type="bibr" rid="bib20">Eschenbacher et al., 2012</xref>), we surmised that, like other loss-of-function MFN2 mutants (<xref ref-type="bibr" rid="bib21">Flannick et al., 2014</xref>; <xref ref-type="bibr" rid="bib51">Steinberg et al., 2015</xref>), MFN2 Q400 could have pathophysiological relevance. We therefore designated it a candidate cardiomyopathy modifier and proceeded with detailed investigations.</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Morphological effects of disease-related MFN2 mutants on mitofusin null and normal mitochondria.</title><p>(<bold>A</bold>) Hypothetical structures of human MFN2 in the basal/closed (left) and active/open (right) conformations. Domains are color-coded: green, GTPase; red, first heptad repeat (HR1); blue, second heptad repeat (HR2). Arrows indicate positions of human disease-linked MFN2 mutants of primary interest. (<bold>B</bold>) Sequencing pherogram from a hypertrophic cardiomyopathy subject showing heterozygous MFN2 R400Q mutation (arrow). (<bold>C</bold>) Immunoblot of wild-type (WT) and mutant MFN2s expressed in Mfn1/Mfn2 double knockout (DKO) murine embryonic fibroblasts (MEFs). In all studies, adenoviral β-gal is negative control; β-actin is loading control. (<bold>D</bold>) Intrinsic fusogenic activity of WT and mutant MFN2 expressed in MFN DKO cells, assayed as increase in mitochondrial aspect ratio compared to β-gal. (<bold>E</bold>) Same as (<bold>D</bold>) except MFNs were expressed in WT MEFs to reveal effects on endogenous MFN1 and MFN2. Unless otherwise stated, in all graphs black is WT MFN2, green is GTPase domain MFN2 mutants, red is HR1 domain MFN2 mutants. Numbers in bars are independent experiments for 6–30 cells per experiment. p-Values used ANOVA and Tukey’s test.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>gnomAD MFN2 coding variants.</title><p>Red font indicates variants found in CM.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-84235-fig1-data1-v1.xlsx"/></supplementary-material></p><p><supplementary-material id="fig1sdata2"><label>Figure 1—source data 2.</label><caption><title>Mitofusin 2 (75 kDa) and β-actin (45 kDa) expression level in MEFs Wt.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84235-fig1-data2-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Fusogenic activities of GTPase-defective, CMT2A-linked MFN2 R94Q, and laboratory-engineered K109A in Mfn1/Mfn2 double knockout (DKO) murine embryonic fibroblasts (MEFs) (left) and WT MEFs (right).</title><p>β-gal and WT MFN2 are from <xref ref-type="fig" rid="fig1">Figure 1</xref>. p-Values calculated using ANOVA and Tukey’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-2"><title>MFN2 Q400 is a dominant suppressor of mitochondrial fusion</title><p>Many CMT2A MFN2 mutations, including prototypical MFN2 T105M, are located within the GTPase domain (<xref ref-type="fig" rid="fig1">Figure 1A</xref>, green region) and lack catalytic GTPase activity (<xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref>). By contrast, MFN2 R400Q (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) is located in the hydrophobic core within the so-called first heptad repeat domain (HR1; <xref ref-type="fig" rid="fig1">Figure 1A</xref>, red region). To better understand the relationship between <italic>MFN2</italic> mutation location, protein dysfunction, and pathophysiological consequence, we compared fusogenic activities of mutant MFN2 Q400 to wild-type (WT) MFN2 and two positionally diverse human CMT2A mutants, MFN2 T105M in the GTPase domain and MFN2 M376V/A in the HR1 domain (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="bibr" rid="bib23">Franco et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Zhou et al., 2021</xref>). An additional CMT2A GTPase domain mutation, MFN2 R94Q, and laboratory-engineered MFN2 K109A (<xref ref-type="bibr" rid="bib13">Detmer and Chan, 2007</xref>), were included as complementary comparators (see <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). Each human MFN2 was expressed at equal levels in murine mitofusin null (<italic>Mfn1/Mfn2</italic> double knockout [DKO]) cells using adenoviral transduction (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="bibr" rid="bib33">Li et al., 2019</xref>). Importantly, using this system the transfected mitofusin proteins are properly inserted into mitochondria and fully functional (<xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref>).</p><p>Mitochondrial aspect ratio (length/width) is commonly used to gauge the relative activity of mitochondrial fusion vs. fission. The normal mitochondrial aspect ratio of ~5–6 in WT murine embryonic fibroblasts (MEFs) is reduced to ~2 in MEFs lacking both mitofusins (Mfn DKO) (compare white bars in <xref ref-type="fig" rid="fig1">Figure 1D and E</xref>). An increase in aspect ratio in Mfn DKO cells reflects intrinsic fusogenic activity of recombinant MFN2 proteins expressed therein (<xref ref-type="bibr" rid="bib22">Franco et al., 2016</xref>). Consistent with an absolute requirement for GTP hydrolysis during mitochondrial fusion, all three GTPase domain MFN2 mutants exhibited diminished fusogenicity compared to WT MFN2 (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; left panel, green bars). Intrinsic fusogenicity of MFN2 M376A and R400Q was similarly impaired (<xref ref-type="fig" rid="fig1">Figure 1D</xref>, red bars).</p><p>Most CMT2A-associated MFN2 mutants do not simply exhibit reduced intrinsic fusogenicity, but dominantly suppress mitochondrial fusion mediated by normal mitofusins 1 and 2. We assayed suppression of mitochondrial fusion by expressing our panel of MFN2 mutants in WT MEFs, which have normal endogenous Mfn1 and Mfn2 and, therefore, a characteristic baseline mitochondrial aspect ratio of 5–6 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, white bar). As expected, expression of WT MFN2 caused mitochondrial hyper-fusion, increasing mitochondrial aspect ratio to ~8 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, black bar). By comparison, all three GTPase domain MFN2 mutants and MFN2 R400Q suppressed normal mitochondrial fusion (i.e. lowered mitochondrial aspect ratio vs. adeno-βgal transduced) in WT cells. Uniquely among the expressed MFN2 mutants, MFN2 M376A did not alter baseline aspect ratio of WT MEF (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>, right panel). Thus, MFN2 R400Q is similar to GTPase domain MFN2 mutants in that it both lacks intrinsic fusogenic activity and dominantly suppresses normal mitochondrial fusion, whereas MFN2 M376A is a straightforward functional null protein without dominant inhibitory effects.</p></sec><sec id="s2-3"><title>MFN2 HR1 mutants have normal GTPase activity and do not impair mitochondrial respiration</title><p>MFN1 and MFN2 are dynamin family GTPases; catalytic GTPase activity is required for mitochondrial fusion (<xref ref-type="bibr" rid="bib6">Chan, 2006</xref>; <xref ref-type="bibr" rid="bib47">Santel and Fuller, 2001</xref>; <xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref>). We asked how suppression of fusion by our panel of MFN2 mutants related to differences in GTPase activity. Adenovirally expressed WT MFN2 accounted for approximately two-thirds of total mitochondrial GTPase activity in transduced mitofusin DKO cells (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, black bar). As expected, MFN2 T105M, R94Q, and K109A each lacked GTPase activity (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, left panel, green bars). Remarkably, GTPase activity of MFN2 R400Q and M376A was the same as WT MFN2, that is, normal (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, red bars). Thus, diminished GTPase activity cannot be the mechanism for impaired fusogenicity of these two MFN2 HR1 domain mutants.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Effects of disease-related MFN2 mutants on catalytic and respiratory function of mitofusin null and normal mitochondria.</title><p>(<bold>A</bold>) GTPase activity of human disease-linked MFN2 mutants expressed in mitofusin double knockout (DKO) murine embryonic fibroblasts (MEFs). (<bold>B</bold>) Loss of inner membrane polarization in WT MEF mitochondria induced by disease-related MFN2 mutants. To the right are representative MitoTracker Green/TMRE co-stained confocal images. (<bold>C</bold>) Seahorse studies of oxygen consumption rate (OCR) in MFN DKO MEFs expressing disease-linked MFN2 mutants. (Left) Average data from three experiments per condition. (Right) Group quantitative results for basal, ATP-linked and maximal respiration (pmol/min/20,000 cells). *p&lt;0.05 vs. WT.p-Values for all studies used ANOVA and Tukey’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig2-v1.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>GTPase activity of, and inner membrane depolarization induced by, GTPase domain CMT2A-linked MFN2 R94Q and laboratory-engineered K109A expressed in Mfn1/Mfn2 double knockout (DKO) murine embryonic fibroblasts (MEFs) (left) and WT MEFs (right), respectively.</title><p>β-gal and WT MFN2 are from <xref ref-type="fig" rid="fig2">Figure 2</xref>. p-Values calculated using ANOVA and Tukey’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig2-figsupp1-v1.tif"/></fig></fig-group><p>Mitochondrial respiration and oxidative phosphorylation of ADP to ATP are driven by an electrochemical gradient across the inner mitochondrial membrane, the so-called ‘proton pump’ (<xref ref-type="bibr" rid="bib38">Madeira, 2018</xref>). Functional electrochemical inner membrane integrity can be assessed using dyes that are concentrated within mitochondria in a voltage-dependent manner; loss of inner membrane electrical polarization abrogates mitochondrial staining. We used tetramethylrhodamine ethyl ester (TMRE) to assess mitochondrial polarization in WT MEFs expressing our panel of MFN2 mutants. Dissipation of the inner membrane electrochemical gradient (mitochondrial depolarization) was provoked by MFN2 T105M, R94Q, and K109A, but not by MFN2 M376A or R400Q (<xref ref-type="fig" rid="fig2">Figure 2B</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, right panel). Thus, for these MFN2 mutants, the ability to induce mitochondrial depolarization corresponds with impaired catalytic GTPase activity.</p><p>The functional consequences of MFN2 mutations on catalytic GTPase activity and electrochemical integrity were further assessed by measuring mitochondrial respiration in DKO MEFs transduced with adeno-MFN2 WT, T105M, M376A, or R400Q. As expected, introducing WT MFN2 into cells lacking mitofusins enhanced all phases of mitochondrial respiration (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, black). By comparison, MFN2 T105M failed to enhance mitochondrial respiration (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, green). Strikingly, MFN2 M376A and R400Q were intermediate in their effects, increasing mitochondrial respiration vs. the complete absence of mitofusins (i.e. vs. β-gal), but seemingly not to the same extent as WT MFN2 (<xref ref-type="fig" rid="fig2">Figure 2C</xref>, red). These data provide further evidence supporting the central relationship between mitochondrial GTPase activity, polarization, and respiration. In the context of our results presented in <xref ref-type="fig" rid="fig1">Figure 1</xref>, these results implicate a different, unidentified mechanism by which MFN2 HR1 domain mutants impair mitochondrial fusion and suppress mitochondrial respiration.</p></sec><sec id="s2-4"><title>MFN2 HR1 domain mutations cause loss of conformational malleability</title><p>Mitofusin protein conformation changes upon activation, transitioning from a closed basal state to an open state that favors mitochondrial fusion (<xref ref-type="bibr" rid="bib22">Franco et al., 2016</xref>). The closed conformation is maintained by peptide–peptide interactions involving MFN2 amino acids 367–384 in the HR1 domain (<xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref>; <xref ref-type="bibr" rid="bib16">Dorn, 2019</xref>). We considered that M376 mutations within the peptide–peptide interaction domain, and the proximity of the MFN2 R400 mutation site to the interacting domain, might alter the ability of these MFN2 mutant proteins to switch conformation. Consistent with this notion, GTPase-defective CMT2A mutant MFN2 T105M transitioned normally from open to closed state, as measured by antagonist and agonist peptide-induced changes in Forster resonance energy transfer (FRET; <xref ref-type="bibr" rid="bib11">Dang et al., 2020</xref>; <xref ref-type="fig" rid="fig3">Figure 3A</xref>, green bars). By contrast, the MFN2 M376A and R400Q FRET signals did not change in the presence of MFN antagonist and agonist peptides that normally provoke the closed or open conformation, respectively (<xref ref-type="fig" rid="fig3">Figure 3A</xref>, red bars; <xref ref-type="bibr" rid="bib22">Franco et al., 2016</xref>). Thus, these MFN2 HR1 domain mutants are defective in their ability to move between open fusion-permissive and closed fusion-limiting conformations, which can explain how mitochondrial fusion is impaired by these mutations despite normal catalytic GTPase activity.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>MFN2 R400Q impairs conformational shifting and suppresses mitochondrial Parkin recruitment, but not mitochondrial motility in neuronal axons.</title><p>(<bold>A</bold>) Forster resonance energy transfer (FRET) studies of conformational switching in disease-linked MFN2 mutants expressed in MFN double knockout (DKO) murine embryonic fibroblasts (MEFs). Antagonist peptide normally induces closed conformation (increase in FRET) and agonist peptide open conformation (decrease in FRET). (<bold>B</bold>) Mitochondrial motility in cultured mouse dorsal root ganglion neuronal processes: representative kymographs are to the right (raw data above; motile mitochondrial emphasized below [red, antegrade; blue, retrograde]).Scale bar 10 μm, Data are n~3 5 DRGs for each independent experiment, statistic is one-way ANOVA. (<bold>C</bold>) mcParkin (red) recruitment to mitochondria in MFN DKO MEFs expressing MFN2 mutants before (baseline) and after FCCP (left, representative confocal micrographs; right, group quantitative data). p-Values calculated using ANOVA and Tukey’s test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig3-v1.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Effects of engineered synthetic MFN2 mutants on mitochondrial Parkin recruitment and mitochondrial motility in neuronal axons.</title><p>(<bold>A</bold>) Mitochondrial motility in cultured dorsal root ganglion (DRG) neuronal processes. Group quantitative data are to the left; representative kymographs are to the right. β-gal and WT MFN2 are from <xref ref-type="fig" rid="fig3">Figure 3</xref>. p-Values calculated using ANOVA and Tukey’s test. (<bold>B</bold>) Representative confocal micrograph showing Parkin localization (red) to mitochondria (green) after FCCP treatment. Arrows point to some co-localization events (yellow). Scale bar 10 μm, Data are n~3 5 DRGs for each independent experiment. (<bold>C</bold>) Parkin aggregation at mitochondria in MFN2 double knockout (DKO) murine embryonic fibroblasts (MEFs) in the absence (-) and presence (+) of FCCP; representative images to the right. MFN2 K109A is GTPase-defective; MFN2 EE constitutively binds Parkin; MFN2 AA cannot bind Parkin.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig3-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-5"><title>MFN2 HR1 domain mutations do not impair mitochondrial motility</title><p>The appellative function of mitofusins is to mediate mitochondrial fusion, but MFN2 has additional non-canonical tasks including to promote mitochondrial transport (<xref ref-type="bibr" rid="bib41">Misko et al., 2010</xref>; <xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Franco et al., 2020</xref>). Indeed, some CMT2A-linked MFN2 mutations dominantly suppress mitochondrial motility, thereby contributing to die-back of long peripheral nerves that require distal mitochondrial delivery for cell renewal and regeneration (<xref ref-type="bibr" rid="bib41">Misko et al., 2010</xref>; <xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref>; <xref ref-type="bibr" rid="bib23">Franco et al., 2020</xref>). Directed mitochondrial transport can readily be measured in cultured neurons (<xref ref-type="bibr" rid="bib12">Dang et al., 2022</xref>; <xref ref-type="bibr" rid="bib19">Dorn and Dang, 2022</xref>). Accordingly, we expressed our representative MFN2 mutants in cultured dorsal root ganglion (DRG) neurons derived from wild-type mice. Consistent with previous observations that mitochondrial fusion and motility can be co-regulated by MFN2 (<xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref>), mitochondrial transport through neuronal processes was suppressed by GTPase-defective MFN2 mutants T105M and K109A (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, green bar), and an MFN2 mutant engineered to mimic phosphorylation at sites that suppress mitochondrial fusion, MFN2 EE (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, gray bar MFN2 E111, E442). Mitochondrial motility in DRG neurons was unaffected by HR1 domain mutants M376A and R400Q (<xref ref-type="fig" rid="fig3">Figure 3B</xref>, red bars) or by an MFN2 mutant engineered to prevent phosphorylation at the fusion-regulatory sites, MFN2 AA (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>, A111A442). Thus, combined abnormalities of mitochondrial fusion and motility exhibited by GTPase-defective MFN2 mutants are dissociated in MFN2 HR1 domain mutants.</p></sec><sec id="s2-6"><title>MFN2 Q400 is non-functional as a mitochondrial Parkin receptor</title><p>MFN2 can initiate mitophagy by switching from a fusion protein into a ‘Parkin receptor’ that recruits cytosolic Parkin to damaged mitochondria (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib56">Xiong et al., 2019</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>). Mitophagic vs. fusogenic properties are determined by the phosphorylation status of MFN2 T111 and S442 (<xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>). Prior studies have suggested that MFN2 functioning as a Parkin receptor and mitophagy effector is important to heart development and/or contractile function (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>; <xref ref-type="bibr" rid="bib49">Song et al., 2015</xref>). Mitochondrial Parkin recruitment by MFN2 WT, T105M, M376A, and R400Q was compared to that evoked by the MFN2 phosphorylation site mutants MFN2 EE that constitutively bind Parkin and MFN2 AA that is incapable of binding Parkin (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>). Parkin translocation from cytosol to mitochondria was stimulated by uncoupling mitochondrial respiration with carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) and visualized as the appearance of mitochondrial Parkin aggregates (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1B</xref>). Baseline cytosolic Parkin localization in the absence of FCCP was not affected by WT MFN2 or any of the naturally occurring MFN2 mutants (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>, FCCP), whereas MFN2 EE promoted spontaneous Parkin aggregation as expected (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>; <xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>). Parkin translocation in response to FCCP was unaffected by MFN2 WT, T105M, K109A, and M376A, but was markedly reduced in cells expressing MFN2 R400Q (<xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>,+FCCP). Indeed, suppression of Parkin recruitment by MFN2 R400Q was similar in magnitude to that of MFN2AA (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>; <xref ref-type="fig" rid="fig3">Figure 3C</xref>, <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C</xref>, +FCCP). Taken together, the results shown in <xref ref-type="fig" rid="fig1">1</xref>—<xref ref-type="fig" rid="fig3">3</xref> reveal a single characteristic of the MFN2 R400Q mutation that distinguishes it from the CMT2A-linked MFN2 mutants: it suppresses Parkin recruitment to depolarized mitochondria.</p></sec><sec id="s2-7"><title>Mfn2 Q400 knock-in mice develop lethal perinatal cardiomyopathy</title><p>Accumulating evidence suggests that MFN-mediated mitochondrial fusion is essential to early embryonic heart development, and that MFN2-Parkin-mediated mitophagy is required for metabolic maturation of perinatal myocardium (<xref ref-type="bibr" rid="bib30">Kasahara et al., 2013</xref>; <xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>). Thus, MFN2 Q400-induced dysfunction of either fusion or mitophagy could underlie its apparent over-representation in human heart disease. The human MFN2 R400Q mutation is sufficiently rare that relating MFN2 Q400 dysfunction to a particular clinical manifestation would require linkage analysis in large families that were not identified in our FCM cohort. Alternately, we reasoned that manifestation of a cardiac phenotype unique to mice carrying the MFN2 R400Q mutation would provide unbiased evidence linking it to in vivo heart disease. To provide continuity with our in vitro studies comparing MFN2 R400Q to CMT2A-associated mutations at T105 and M376, we used CRISPR/Cas9 to engineer human mutations at all three MFN2 sites into the highly homologous mouse <italic>Mfn2</italic> gene (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>Heterozygous knock-in mice from each line were viable, and therefore interbred to expand colonies. Mutant allele frequency of resulting offspring, expected to be ~50%, was significantly lower in Mfn2 T105M mice, and trended lower in Mfn2 R400Q mice (<xref ref-type="fig" rid="fig4">Figure 4A</xref>). Genotyping of 7-day-old pups revealed no homozygous mutant Mfn2 T105M mice and an abnormally low percentage of homozygous mutant Mfn2 R400Q mice, whereas mutant allele distribution of Mfn2 M376V mice followed Mendelian norms (<xref ref-type="fig" rid="fig4">Figure 4B</xref>). Analysis of embryos from timed crosses revealed no homozygous Mfn2 T105M mice as early as E12.5, recapitulating early embryonic lethality described in germline Mfn1 and Mfn2 knockout mice (<xref ref-type="bibr" rid="bib7">Chen et al., 2003</xref>); heterozygous Mfn2 T105M mice had normal hearts and a neurological phenotype to be reported separately. Heterozygous and homozygous Mfn2 M376V mice likewise had normal hearts. We interrogated the apparent paucity of homozygous Mfn2 R400Q KI mice by interbreeding surviving homozygotes (Mfn2 Q/Q400 mice). Litter size from homozygous crosses, reflecting survival of Q/Q400 mice, was normal at E18.5. However, approximately one-third of Q/Q400 fetuses died between E18.5 and birth (P0), and another approximately one-third of Q/Q400 pups succumbed by P7, after which there was no further abnormal mortality (<xref ref-type="fig" rid="fig4">Figure 4C</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Perinatal cardiomyopathy in Mfn2 Q/Q400 mice.</title><p>(<bold>A, B</bold>) Mutant allele frequencies (<bold>A</bold>) and genotypes (<bold>B</bold>) from heterozygous crosses of Mfn2 T105M, M376V, and R400Q knock-in mice (CRISPR/Cas9 knock-in strategies are given in the figure supplement). Expected values are shown as dotted lines. Homozygous mice were absent for T105M and fewer than expected for R400Q. (<bold>C</bold>) Fetal and early postnatal lethality of homozygous R400Q knock-in mice (Q/Q400) reported as mice/litter at different time points. Controls (white) are C57/Bl6. Inset shows an E18.5 Q/Q400 litter having a degenerated fetus (arrowhead) and a live, non-viable fetus (arrow). (<bold>D</bold>) Hematoxylin and eosin-stained sections of left ventricular myocardium from P0 Q/Q400 mice with (left) and without (right) cardiomyocyte vacuolization. (<bold>E</bold>) Ultrastructural studies of Q/Q400 myocardium revealing myofibrillar degeneration (arrow), empty ‘ghost’ mitochondria (arrowheads) and mitochondrial fragmentation; wild-type control is shown for comparison on the right. *p&lt;0.05 vs. expected (<bold>A</bold>, Fisher’s exact test) or control (<bold>C</bold>, Student’s <italic>t</italic>-test).</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>CRISPR engineering of disease-linked human MFN2 mutants into the mouse genome.</title><p>(<bold>A</bold>) Mfn2 R400Q; (<bold>B</bold>) Mfn2 T105M; and (<bold>C</bold>) Mfn2 M376V. For each mouse line, the left of the panel depicts the gene editing strategy, and to the right Sanger sequence of the resulting nucleotide changes. Note that no homozygous mice or embryos as early as E12.5 were identified for Mfn2 T105M in &gt;40 breedings.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Quantitative mean data for transmission electron micrograph (TEM) studies of Mfn2 Q/Q400 mouse pups.</title><p>On the left are representative TEMs of myocardium. To the right are mean ± SEM data. Numbers are individual mice with &gt;10 images per mouse; p-values by unpaired <italic>t</italic>-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig4-figsupp2-v1.tif"/></fig></fig-group><p>Histological examination of two litters of P0 Q/Q400 mice by a blinded Washington University veterinary pathologist revealed ‘foci of cardiomyocyte vacuolation’ in the myocardia of over half of the hearts (<xref ref-type="fig" rid="fig4">Figure 4D</xref>). No other organs showed any histological or structural abnormalities. Ultrastructural examination revealed loss of myofibrillar integrity with mitochondrial scarcity, disorganization, fragmentation, and degeneration (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>) Thus, Mfn2 Q/Q400 mice develop a highly specific, incompletely penetrant late fetal/early perinatal cardiomyopathy.</p></sec><sec id="s2-8"><title>Transcriptional and metabolomic profiling of MFN2 Q400 cardiomyopathy identifies signatures specific for cardiac pathology</title><p>Transcriptional profiling can provide insights into the mechanisms underlying cardiac phenotypes produced by genetic variation (<xref ref-type="bibr" rid="bib1">Aronow et al., 2001</xref>). We performed RNA sequencing on E18.5 MFN2 Q/Q400 mouse hearts and their WT controls; E18.5 was selected because there was little mouse drop-out at this time point (see <xref ref-type="fig" rid="fig4">Figure 4C</xref>). Unsupervised clustering of dysregulated Q/Q400 cardiac mRNAs (p-value&lt;0.02, FDR &lt; 0.05, fold change &gt;2 vs. wild-type) segregated hearts into those having near-normal mRNA levels (designated nominal; Q400n) and those manifesting an abnormal transcriptional profile (designated anomalous; Q400a) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). Interrogation of mRNA levels of genes central to mitochondrial function, including respiratory enzymes encoded by the mitochondrial genome and nuclear-encoded mitochondrial biogenesis and mitochondrial dynamics genes (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplements 1</xref> and <xref ref-type="fig" rid="fig5s2">2</xref>), confirmed segregation between normal and abnormal hearts. Gene ontology (GO) analysis of dysregulated Q400a transcripts categorized mRNAs with lower expression in Q400a hearts overwhelmingly to metabolic and mitochondrial disease pathways (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). By contrast, genes with increased expression in the same hearts were linked to multiple injury responses (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), likely reflecting a compensatory reaction to myocardial degeneration. The distinction between Q400a and Q400n hearts was noteworthy for SOD2 and major cardiac expressed GPX mRNAs, respectively encoding mitochondrial superoxide dismutase and glutathione peroxidases that are central to mitigating mitotoxicity from reactive oxygen species (ROS) (<xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Transcriptional and metabolomic profiling of Mfn2 Q/Q400 mouse hearts identifies metabolic abnormalities characteristic of mitophagy defects.</title><p>(<bold>A</bold>) Heat map of gene expression in individual Q400 and wild-type (WT) mouse hearts. (<bold>B</bold>) Heat map of anomalous Q400a mouse heart gene expression (top) and pie charts describing major KEGG functionally annotated pathway categories of up- (left) and downregulated (right) transcripts. (<bold>C</bold>) Individual heart mRNA levels for reactive oxygen species (ROS)-modulating enzymes. SOD, superoxide dismutase; GPX, glutathione peroxidase. Results shown are for the cardiac-expressed isoforms defined as WT CPM &gt;100. Each point is an individual mouse heart. p-Values by ANOVA. (<bold>D</bold>) Metabolomics heat map showing unsupervised clustering of individual Q/Q400 and WT mouse hearts. (<bold>E–H</bold>) Relative expression of genes from indicated metabolic pathways. Blue is significantly decreased in MFN2 Q/Q 400a hearts; red is significantly increased; gray is no significant difference.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Expression of mitochondrial DNA-encoded respiratory genes (top) and mitochondrial biogenesis genes (bottom) in late fetal Mfn2 Q/Q400 mouse hearts.</title><p>Each point is an individual mouse heart. p-Values by ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig5-figsupp1-v1.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>Expression of mitochondrial dynamics factor mRNAs in late fetal Mfn2 Q/Q400 mouse hearts.</title><p>Each point is an individual mouse heart. p-Values by ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig5-figsupp2-v1.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Metabolite levels in Mfn2 Q/Q400 mouse pup hearts.</title><p>Each point is an individual mouse heart. ‘Mutant’ indicates both abnormal and normal MFN2 Q400 mutants. p-Values from unpaired <italic>t</italic>-test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig5-figsupp3-v1.tif"/></fig></fig-group><p>The abnormal metabolic transcriptional signature of Q400a mouse hearts prompted metabolomics studies of individual newborn mouse hearts. As with gene expression, metabolomics segregated MFN2 Q/Q400 mice into Q400a and Q400n (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). Metabolic differentiation between Q400a and Q400n was largely driven by abnormally low levels of a preferred metabolic substrate for fetal myocardium, lactate (<xref ref-type="bibr" rid="bib36">Lopaschuk et al., 1992</xref>; <xref ref-type="bibr" rid="bib45">Piquereau and Ventura-Clapier, 2018</xref>) in Q400a hearts. Levels of C2 fatty acid acylcarnitines and several amino acids were also diminished (<xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). Specific interrogation of metabolic pathway gene expression in MFN2 Q400 fetal hears revealed broad downregulation of mRNAs encoding fatty acid entry, glycolysis, tricarboxylic cycle, and oxidative phosphorylation pathway proteins (<xref ref-type="fig" rid="fig5">Figure 5E–H</xref>). Thus, the development of cardiomyopathy in Mfn2 Q/Q400 fetuses and neonates corresponds with signature abnormalities of myocardial metabolism.</p></sec><sec id="s2-9"><title>Cardiac myocyte mitophagy is suppressed by MFN2 Q400</title><p>Our in vitro studies revealed MFN2 Q400 to be defective in recruiting Parkin to mitochondria, suggesting that this mutation might adversely impact Parkin-mediated mitophagy. This notion gained support from our observation that the MFN2 Q400 fetal heart profile of abnormal fatty acid entry, glycolysis, tricarboxylic cycle, and oxidative phosphorylation pathway gene expression (see <xref ref-type="fig" rid="fig5">Figure 5</xref>) recapitulates transcriptional changes evoked by experimentally interrupting MFN2-Parkin-mediated mitophagy in perinatal hearts (<xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>). Importantly, this mRNA profile has little similarity to the transcriptional signature provoked by suppressing mitochondrial fusion in embryonic myocardium (<xref ref-type="bibr" rid="bib30">Kasahara et al., 2013</xref>). Given that MFN2 Q400 had only a modest effect on mitochondrial respiration (see <xref ref-type="fig" rid="fig2">Figure 2C</xref>), our findings suggested that the disturbances in myocardial metabolism induced by MFN2 Q400 might be a consequence of interrupting MFN2-Parkin-mediated mitophagy.</p><p>To better understand the impact of MFN2 R400Q on mitophagy in fetal heart cells, we expressed WT or mutant MFN2s in H9c2 rat cardiomyoblasts that retain features of embryonic cardiac myocytes (<xref ref-type="bibr" rid="bib26">Hescheler et al., 1991</xref>; <xref ref-type="bibr" rid="bib31">Kuznetsov et al., 2015</xref>; <xref ref-type="fig" rid="fig6">Figure 6A</xref>). First, we defined the time courses for FCCP-induced mitochondrial Parkin translocation (measured with mcParkin; <xref ref-type="bibr" rid="bib42">Narendra et al., 2008</xref>), mitochondrial engulfment by autophagosomes (measured as mitochondria-LC3-GFP overlay; <xref ref-type="bibr" rid="bib29">Jackson et al., 2005</xref>), and for mitochondrial delivery to lysosomes (measured using MitoQC; <xref ref-type="bibr" rid="bib55">Williams et al., 2017</xref>) in H9c2 cells expressing WT MFN2. As expected, different stages of mitophagy progressed with different temporal patterns (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Remarkably, each of the stages of mitophagy was markedly delayed in H9C2 cells expressing MFN2 Q400 at an equivalent level (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Mitophagy slowly increased over longer time periods in MFN2 Q400 cells, likely reflecting MFN2-independent mitochondrial Parkin recruitment (<xref ref-type="bibr" rid="bib43">Ordureau et al., 2014</xref>).</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>MFN2 Q400 uniquely suppresses early and late mitophagy in cardiomyoblasts.</title><p>(<bold>A</bold>) Adenoviral expression of MFN2s in H9c2 cells. (<bold>B</bold>) Time courses of mitochondrial Parkin aggregation (circles), mitochondrial engulfment by autophagosomes (squares), and mitochondrial delivery to lysosomes (diamonds) in WT MFN2-expressing H9c2 cells after FCCP stimulation. Representative images are to the right. (<bold>C</bold>) Comparative time courses for mitochondrial Parkin aggregation (left), mitochondrial engulfment by autophagosomes (middle), and mitochondrial delivery to lysosomes (right) in MFN2 WT (black) and Q400 (red) expressing H9c2 cells. n = 3–4, *p&lt;0.05 vs. pre-FCCP (time 0); #p&lt;0.05 vs. WT at same time point (two-way ANOVA). (<bold>D, E</bold>) mcParkin aggregation 1 hr after FCCP treatment (<bold>D</bold>) and mitolysosome formation 8 hr after FCCP treatment (<bold>E</bold>) of H9c2 cells transduced with MFNs. Experimental n is shown in bars; stats by two-way ANOVA. Representative confocal images are shown in <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Mitofusin 2 (75kDa) and GAPDH (36 kDa) expression level in H9c2 cells.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-84235-fig6-data1-v1.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig6-v1.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Representative mcParkin (<bold>A</bold>) and MitoQC (<bold>B</bold>) confocal images showing mitophagy provoked by FCCP in H9c2 cardiomyoblasts expressing WT and disease-linked MFN2 mutants.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig6-figsupp1-v1.tif"/></fig><fig id="fig6s2" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 2.</label><caption><title>Seahorse studies of oxygen consumption rate (OCR) in cultured H9c2 cardiomyoblasts expressing disease-linked MFN2 mutants.</title><p>(Lleft) Average data from 5 to 7 experiments per condition. (Right) Group quantitative results for basal, ATP-linked, and maximal respiration (pmol/min/20,000 cells). Statistical comparisons used ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig6-figsupp2-v1.tif"/></fig></fig-group><p>As in Mfn2 DKO cells (see <xref ref-type="fig" rid="fig3">Figure 3C</xref>), CMT2A-associated MFN2 T105M and M376A expressed in H9c2 cells promoted normal FCCP-stimulated Parkin recruitment to mitochondria, whereas Parkin aggregation was impaired in cardiomyoblasts expressing MFN2 R400Q (<xref ref-type="fig" rid="fig6">Figure 6D</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>); mitophagy measured as mitolysosome formation followed the same pattern (<xref ref-type="fig" rid="fig6">Figure 6E</xref>, <xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). Mitophagy-defective MFN2 Q400 was less effective than WT MFN2 R400 in promoting H9c2 cardiomyoblast mitochondrial respiration (<xref ref-type="fig" rid="fig6s2">Figure 6—figure supplement 2</xref>), recapitulating its effects in MEFs (see <xref ref-type="fig" rid="fig2">Figure 2C</xref>). These findings further support the concept that the primary functional defect responsible for cardiac-specific abnormalities in MFN2 Q400 knock-in mice is impaired Parkin-mediated mitophagy.</p></sec><sec id="s2-10"><title>Mfn2 R400Q suppresses compensatory mitophagy induced by doxorubicin and increases sensitivity to doxorubicin-induced cardiomyopathy</title><p>Taken together, the above results point to defective mitophagy as a central mechanism underlying murine perinatal cardiomyopathy induced by the Mfn2 R400Q mutation. Based on prior reports (<xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>), developmentally regulated Mfn2-Parkin-mediated mitophagy is essential for myocardial metabolic maturation in the perinatal period, whereas in adult hearts the same mitophagy mechanism mediates mitochondrial quality control (<xref ref-type="bibr" rid="bib49">Song et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Song et al., 2017</xref>). We asked whether, despite having normal cardiac function under basal conditions, surviving Q/Q400 mice might have a residual mitophagy defect manifested only in the face of an extrinsic mitochondrial insult. Doxorubicin, an anti-cancer chemotherapeutic with well-characterized dose-dependent cardiotoxic effects mediated in large part by mitochondrial dysfunction (<xref ref-type="bibr" rid="bib54">Wallace et al., 2020</xref>; <xref ref-type="bibr" rid="bib48">Schirone et al., 2022</xref>), is such an insult. Therefore, we evaluated dose-dependent doxorubicin-induced cardiomyoblast toxicity in cultured H9c2 cells. Expression of MFN2 Q400 increased overall doxorubicin-stimulated H9c2 cell death and TUNEL apoptosis marker labeling (<xref ref-type="fig" rid="fig7">Figure 7A and B</xref>), while suppressing mitochondrial Parkin recruitment and mitolysosome formation (<xref ref-type="fig" rid="fig7">Figure 7C</xref>). Compared to WT MFN2 R400, expression of MFN2 Q400 increased baseline mitochondrial ROS to levels comparable to those provoked by doxorubicin in normal cells (<xref ref-type="fig" rid="fig7">Figure 7D</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Mfn2 R400Q impairs reactive mitophagy and amplifies cardiomyocyte toxicity induced by doxorubicin in vitro and in vivo.</title><p>(<bold>A</bold>) Cell death curves provoked by increasing concentrations of doxorubicin (overnight treatment) in WT MFN2 (R400) and MFN2 Q400 transduced H9c2 cardiomyoblasts. Representative live-dead images corresponding to each group are to the right; scale bar 100 um. (<bold>B</bold>) TUNEL labeling of apoptotic H9c2 cardiomyoblasts treated with 10 uM doxorubicin overnight. Dotted line is basal level in absence of doxorubicin. (<bold>C</bold>) Reactive mitophagy measured as Parkin aggregation (left) and mitolysosome formation (right) in doxorubicin-treated H9c2 cardiomyoblasts. Dotted lines show basal levels in absence of doxorubicin. (<bold>D</bold>) Flow cytometric analysis of doxorubicin effects on mitochondrial-derived ROS in H9c2 cardiomyoblasts expressing WT MFN2 R400 or mutant MFN2 Q400. Representative (of three independent experiments) histograms are on the left; mean group data are on the right. *p&lt;0.05 vs. same group without doxorubicin; #p&lt;0.05 vs. WT cells treated identically (ANOVA). (<bold>E</bold>) Echocardiography of WT (R/R400), heterozygous (R/Q400), and homozygous (Q/Q400) knock-in mice 4 and 7 d after receiving doxorubicin (20 ug/g, intraperitoneal injection). LVEDD is left ventricular (LV) end diastolic dimension, which increases with dilated cardiomyopathy; FS is LV fractional shortening, which decreases in dilated cardiomyopathy; calculated LV mass increases in dilated cardiomyopathy. Representative m-mode echos are to the right. (<bold>F</bold>) Gravimetric heart weights 7 d after doxorubicin, indexed to tibial length. (<bold>G</bold>) MitoQC visualization of LV cardiomyocyte mitolysosomes. Group mean quantitative data on the left; representative confocal images on the right. Mitolysosomes are bright orange spots; scale bar is 10 um. (<bold>E–G</bold>): *p&lt;0.05 vs. WT at the same time; $p=0.05–0.075 vs. WT at the same time; #p&lt;0.05 vs. same genotype pre-doxorubicin; @p=0.05–0.075 vs. same genotype pre-doxorubicin; statistical comparisons used one- (<bold>F</bold>, <bold>G</bold>) or two-way (<bold>E</bold>) ANOVA.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-84235-fig7-v1.tif"/></fig><p>Administration of doxorubicin to mice provokes mitochondrial injury that can lead to dilated cardiomyopathy (<xref ref-type="bibr" rid="bib14">Dhingra et al., 2014</xref>). We compared the cardiac response to doxorubicin between young adult wild-type (R/R 400), heterozygous (R/Q 400), and surviving homozygous (Q/Q 400n) Mfn2 R400Q knock-in mice. Left ventricular (LV) chamber dimension at end-diastole (LVEDD) and calculated LV mass increased, and LV ejection performance (fractional shortening; FS) decreased to a greater extent in homozygous Mfn2 Q/Q 400 knock-in mice than WT or heterozygous mice (<xref ref-type="fig" rid="fig7">Figure 7E</xref>). Likewise, gravimetric heart weights were greater in doxorubicin-treated Mfn2 Q/Q400 mice than the other groups (<xref ref-type="fig" rid="fig7">Figure 7F</xref>). As in cultured H9c2 cardiomyoblasts, the exaggerated Mfn2 Q/Q400 mouse cardiotoxic response to doxorubicin was associated with diminished reactive mitophagy (<xref ref-type="fig" rid="fig7">Figure 7G</xref>).</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Our studies describe two major findings. First, we provide plausible evidence for a contribution of impaired MFN2-Parkin-mediated mitophagy to myocardial disease. Our conclusions are supported by a statistical genetic association in human cardiomyopathy, cardiac-specific phenotypes in knock-in mice expressing a candidate human mutation, and mechanistic studies defining the effects of the R400Q mutant MFN2 protein on mitophagy in cultured cardiomyoblasts and in vivo mouse hearts. Second, we describe a novel functional consequence of natural MFN2 mutation wherein an impaired ability to shift protein conformation leads to concomitant defects in both mitochondrial fusion and mitophagy, but a normal ability to promote mitochondrial transport. We surmise that the combination of mitophagy and fusion defects evokes cardiac disease, whereas combined mitochondrial motility and fusion defects described for many CMT2A-linked MFN2 mutations (including those studied herein) provoke peripheral neuropathy. This paradigm provides a mechanistic basis for tissue specificity of diseases evoked by MFN2 mutations.</p><p>Conventional hypertrophic and dilated cardiomyopathies are caused by mutations of sarcomeric proteins (<xref ref-type="bibr" rid="bib40">Mazzarotto et al., 2020</xref>). The current data suggest that myocardial-specific clinical disease can also be induced by mutational disruption of mitophagy. As an initiator/effector of both mitochondrial fusion and Parkin-mediated mitophagy, MFN2 orchestrates cardiomyocyte fate in embryonic (<xref ref-type="bibr" rid="bib30">Kasahara et al., 2013</xref>) and perinatal hearts (<xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>). Under normal circumstances, mitofusin–mitofusin binding mediates mitochondrial fusion, and mitofusin–Parkin binding promotes mitophagy; these are mutually exclusive functions regulated by PINK1 kinase (<xref ref-type="bibr" rid="bib34">Li et al., 2022</xref>). Thus, non-phosphorylated WT MFN2 promotes MFN-MFN-mediated fusion, but cannot bind Parkin. MFN2 phosphorylation on S378 extinguishes fusion (<xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref>) and on T111 and S442 enables Parkin binding to initiate mitophagy (<xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>). MFN2 phosphorylation on these residues and its control of mitochondrial fate are mechanistically linked by altered MFN2 protein partnering as a consequence of phosphorylation-induced changes in MFN2 conformation (<xref ref-type="bibr" rid="bib17">Dorn, 2020</xref>). Here, we considered that the location of the MFN2 R400Q and M376A mutations near PINK1-phosphorylatable MFN2 S378 and S442 might alter MFN2 conformational switching. Indeed, FRET studies revealed impaired transitioning of both MFN2 R400Q and M376A from the open/fusion-active conformation to the closed/fusion-inactive but mitophagy-permissive conformation. By comparison, GTPase-defective MFN2 mutants readily changed conformation. Our data do not indicate that these two HR2 domain mutations are permanently fixed in either conformational state, but that their transitioning from one conformation to the other is retarded.</p><p>Lack of conformational malleability did not distinguish between the cardiomyopathy- vs. the neuropathy-associated MFN2 mutants. Neither did impaired catalytic activity. While most CMT2A-associated MFN2 mutations occur in the GTPase domain, MFN2 M376A/V is in the HR1 domain and, like R400Q, has normal GTPase activity. Here, mitochondria expressing GTPase-defective MFN2 mutants were both fragmented (from impaired fusion) and depolarized (from degeneration of the mitochondrial respiratory chain). Consistent with respiratory impairment, Seahorse studies revealed severely depressed mitochondrial oxygen consumption in MEFs and H9c2 cells expressing GTPase-defective MFN2 mutants. By contrast, MFN2 HR1 domain mutants M376A and R400Q had normal GTPase activity; mitochondria expressing these mutants, while fragmented, were normally polarized and with only mildly impaired respiration compared to WT MFN2. These findings suggest that mitochondrial depolarization (rather than just fragmentation) may play an important pathological role in CMT2A, but not cardiomyopathy.</p><p>Our data provide a scientific foundation supporting consideration of human genetic mutations that suppress cardiomyocyte mitophagy as candidate risk modifiers for myocardial disease. For MFN2 R400Q, the genetic association between this mitophagy-modifying mutation and human cardiomyopathy is intriguing. However, the mutation is sufficiently rare that it is not possible from genetic data alone to define its contribution to clinical heart disease. While absence of MFN2 Q400 homozygosity in humans could reflect severe early cardiac pathology as manifested by our KI mice, it may simply be the consequence of its rarity. It is worth considering that the low prevalence of this mutation compared to non-synonymous MFN2 mutations in the same HR1 domain, and its over-representation in individuals of African descent, could also reflect negative selection throughout modern human evolution of an ancient and harmful gene variant. Consistent with this idea, the split phenotype of Mfn2 Q400 KI mice, that is, Q400a mice that succumbed to cardiomyopathy during the critical perinatal developmental period vs. Q400n mice that survived to adulthood with apparently normal hearts, belies the common underlying defect in cardiomyocyte mitophagy. We surmise that Q400 mice suffering from developmental mitophagic cardiomyopathy as late fetuses or early pups suffered from metabolic abnormalities and failed to upregulate ROS-managing enzymes. By comparison, Q400 mice that did not develop the spontaneous perinatal cardiomyopathy were better compensated against baseline ROS and metabolic derangements, yet remained hyper-sensitive to the extrinsic mitochondrial stress induced by doxorubicin because reactive mitophagy was impaired.</p><p>Finally, the Mfn2 Q400 KI mouse phenotype may provide fresh insights into the relative importance of mitochondrial fusion vs. mitophagy in hearts. We CRISPR engineered three human MFN2 mutations into the mouse genome. All three MFN2 mutations, T105M, M376A/V, and R400Q, exhibited impaired fusogenicity, but only MFN2 T105M provoked mitochondrial depolarization, abnormally low respiration, and impaired mitochondrial motility. This mutation induced early embryonic lethality when homozygous and caused a CMT2A-like neuropathy (to be described elsewhere) that spared the heart in heterozygous mice. Both M376A/V and R400Q were impaired in their ability to change conformation, explaining loss of function despite normal catalytic GTPase activity. However, only R400Q adversely affected Parkin localization to depolarized mitochondria, and therefore mitophagy, and of the three knock-in mouse lines only R400Q mice exhibited cardiac involvement.</p><p>In conclusion, the current findings point to MFN2 and potentially other mitophagy signaling pathways as candidate genetic modifiers of cardiomyopathy. In the context of MFN2 mutations, these data extend the paradigm that specific functional defects exhibited by mutant MFN2 proteins determine organ system disease involvement.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene<break/>(<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>Mfn-2</italic></td><td align="left" valign="bottom">NCBI Gene</td><td align="left" valign="bottom">Gene ID: 170731</td><td align="left" valign="bottom">MFN2<break/>ENSMUSG00000029020</td></tr><tr><td align="left" valign="bottom">Gene<break/>(human)</td><td align="left" valign="bottom"><italic>MFN-2</italic></td><td align="left" valign="bottom">NCBI Gene</td><td align="left" valign="bottom">Gene ID: 9927</td><td align="left" valign="bottom">MFN2<break/>ENSG00000116688</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mfn2 R400Q knock-in mice</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 400</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mfn2 T105M knock-in mice</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 105</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mfn2 M376V knock-in mice</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 376</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>M. musculus</italic>)</td><td align="left" valign="bottom">C57BL/6J mice</td><td align="left" valign="bottom">C57Bl/6</td><td align="left" valign="bottom">The Jackson Laboratory:<break/>000664</td><td align="left" valign="bottom">C57Bl/6</td></tr><tr><td align="left" valign="bottom">Cell line<break/>H9c2<break/>(rat myoblast)</td><td align="left" valign="bottom">Cardiomyoblast</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1446</td><td align="left" valign="bottom">Rat embryonic cardiomyoblast</td></tr><tr><td align="left" valign="bottom">Cell line<break/>Mfn1/Mfn2 null<break/>(<italic>M. musculus</italic>)</td><td align="left" valign="bottom">Mfn1 and Mfn2 double knock out MEFs</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-2993</td><td align="left" valign="bottom">Murine embryonic fibroblasts</td></tr><tr><td align="left" valign="bottom">Cell line<break/>DRG neuronal cells</td><td align="left" valign="bottom">Adult mouse dorsal root ganglion</td><td align="left" valign="bottom">From 8- to 12-week-old C57BL/6J using enzymatic dissociation.</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib23">Franco et al., 2020</xref></td></tr><tr><td align="left" valign="bottom">Cell line<break/>mouse embryonic fibroblast</td><td align="left" valign="bottom">MEFs WT</td><td align="left" valign="bottom">From E.14.5 pups from C57BL/6J using enzymatic dissociation</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://pubmed.ncbi.nlm.nih.gov/18265203/">https://pubmed.ncbi.nlm.nih.gov/18265203/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Adenovirus<break/>Mito-Ds-Red2</td><td align="left" valign="bottom">Signagen</td><td align="left" valign="bottom">Cat# 12259</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Adenovirus<break/>Cre-recombinase</td><td align="left" valign="bottom">Vector Biolabs</td><td align="left" valign="bottom">Cat# 1794</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2T105M</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2R94Q</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2R400Q</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Human adenovirus type 5 (dE1/E3), with Mfn2R400Q</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2K109A</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2M376A</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-MFN2WT</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-hFRETMFN22WT</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-hFRETMFN2R94Q</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-hFRETMFN2K109A</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Human adenovirus type 5 (dE1/E3), with Mfn2K109A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-hFRETMFN2M376A</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-hFRETMFN2T105M</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom"/><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib24">Franco et al., 2022</xref></td></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-LC3-GFP</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Human adenovirus type 5 (dE1/E3), with LC3 for autophagy</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-mCherry-Parkin</td><td align="left" valign="bottom">Gift from Dr. Åsa Gustafsson</td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human adenovirus type 5 dE1/E3)</td><td align="left" valign="bottom">Ad-mitoQC</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Human adenovirus type 5 (dE1/E3), with mitoQC for mitophagy</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Mfn-2 (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab56889</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-COX-IV (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab16056</td><td align="char" char="." valign="bottom">1:1000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-GAPDH (mouse monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab82245</td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-β-actin (unconjugated monoclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat# 66009-1</td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Goat anti-rabbit IgG</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# 31460</td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Peroxidase-conjugated anti-mouse IgG</td><td align="left" valign="bottom">Cell Signaling</td><td align="left" valign="bottom">Cat# 7076S</td><td align="char" char="." valign="bottom">1:3000</td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2R400Q knock-in mouse (forward)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 400</td><td align="left" valign="bottom"><named-content content-type="sequence">GGCATGTATGTGTAGGTCAGAG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 R400Q knock-in mouse (reverse)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 400</td><td align="left" valign="bottom"><named-content content-type="sequence">CCCAGCTCCTCTGATTTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 R400Q knock-in mouse (sequencing)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 400</td><td align="left" valign="bottom"><named-content content-type="sequence">CAGGTCTCCTTCCACCTTTAC</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 T105M knock-in mouse (forward)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 105</td><td align="left" valign="bottom"><named-content content-type="sequence">TGTTTACTTTGGAAGTAGGCAGTCT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 T105M knock-in mouse (reverse)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 105</td><td align="left" valign="bottom"><named-content content-type="sequence">TTGTTCTTGGTGTCCCACTCTGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 T105M knock-in mouse (sequencing)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 105</td><td align="left" valign="bottom"><named-content content-type="sequence">TCGATGCTTAATGAGTGCTGCTGG</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 M376V knock-in mouse (forward)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 376</td><td align="left" valign="bottom"><named-content content-type="sequence">GTCCGGGCCAAGCAGATTGCAGAGGCCGTTCGTCTCATCATGGATTCCCTGCACATCGCAGCTCAGGAGCAGCGGTGAGA</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 M376V knock-in mouse (reverse)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 376</td><td align="left" valign="bottom"><named-content content-type="sequence">GGTAGTAAAGAGCCTTTCTAGCTGAT</named-content></td></tr><tr><td align="left" valign="bottom">Sequence-based reagent</td><td align="left" valign="bottom">mMFN2 M376V knock-in mouse (sequencing)</td><td align="left" valign="bottom">DornLab</td><td align="left" valign="bottom">Knock-in mice generated with point mutation in position 376</td><td align="left" valign="bottom"><named-content content-type="sequence">TTTCGAGAGGCAGTTTGAGGTAA</named-content></td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">GTPase-Glo Assay</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat# V7681</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mitofusin agonist<break/>TAT-MP-1</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Franco A et al., Nature 2016</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Mitofusin antagonist<break/>TAT-MP-1</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Franco A et al., Nature 2016</td></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">L-Glutamine</td><td align="left" valign="bottom">Gibco</td><td align="left" valign="bottom">Cat# 25030-149</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Goat serum</td><td align="left" valign="bottom">Jackson ImmunoResearch</td><td align="left" valign="bottom">Cat# 005-000121</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Doxorubicin</td><td align="left" valign="bottom">Sigma</td><td align="char" char="." valign="bottom">44583</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Glutaraldehyde</td><td align="left" valign="bottom">Electron Microscopy Science</td><td align="left" valign="bottom">Cat# 16216</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoTracker Green</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# M7514</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">FCCP</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# C2920</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Calcein AM</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# C3100MP</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hematoxylin-eosin</td><td align="left" valign="bottom">Sigma</td><td align="left" valign="bottom">Cat#: GHS116 &amp; HT110116</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">TUNEL</td><td align="left" valign="bottom">Promega</td><td align="left" valign="bottom">Cat#: G3250</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Hoechst</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# H3570</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoTracker Orange</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# M7510</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">Tetramethylrhodamine ethyl ester</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# T-669</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical compound, drug</td><td align="left" valign="bottom">MitoSOX Red</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">Cat# M36008</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ImageJ</td><td align="left" valign="bottom">A. Schneider</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.net/Sholl_Analysis">https://imagej.net/Sholl_Analysis</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Partek Flow</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.partek.com/partek-flow/">https://www.partek.com/partek-flow/</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FlowJo 10 software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.flowjo.com/solutions/flowjo/downloads/">https://www.flowjo.com/solutions/flowjo/downloads/</ext-link></td><td align="left" valign="bottom">N/A</td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Human study populations</title><p>Heart failure (1117 Caucasian; 628 African American) and non-failing control subjects (625 Caucasian; 628 African American) from the Cincinnati Heart Study (<xref ref-type="bibr" rid="bib35">Liggett et al., 2008</xref>; <xref ref-type="bibr" rid="bib39">Matkovich et al., 2010</xref>; <xref ref-type="bibr" rid="bib5">Cappola et al., 2011</xref>) and hypertrophic cardiomyopathy (240 Caucasian; 46 African American) had all <italic>MFN2</italic> exons individually sequenced to identify DNA sequence variants. Additionally, 424 individuals (281 probands) with FCM from the DCM Precision Medicine Study (<xref ref-type="bibr" rid="bib28">Huggins et al., 2022</xref>; <xref ref-type="bibr" rid="bib53">Trachtenberg et al., 2022</xref>) were screened to detect any <italic>MFN2</italic> mutations suitable for linkage analysis; none were identified. Overall and race-specific <italic>MFN2</italic> allele frequencies were compared to non-failing controls from the Cincinnati Heart Study and to the gnomAD data set of 141,456 individuals from various racial backgrounds.</p></sec><sec id="s4-2"><title>Cell lines</title><p><italic>Mfn1/Mfn2</italic> double null MEFs fibroblasts were purchased from American Type Culture Collection (ATCC Manassas, VA, CRL-2994). Normal MEFs were prepared by enzymatic dissociation from embryonic day E.13.5–14.5 C57BL/6J mice (The Jackson Laboratory, Cat# 000664). H9c2 rat cardiomyoblasts were purchased from American Type Culture Collection (ATCC, CRL-1446). MEFs and H9c2 cells were cultured at 37°C, 5% CO<sub>2</sub>-95% air in Dulbecco’s minimal essential medium (DMEM) containing glucose (4.5 g/l) (Thermo Fisher Scientific, 11965-084) with 10% (v/v) fetal bovine serum (FBS; Gibco, Gaithersburg, MD, Cat# 26140-079), 1× nonessential amino acids (Gibco, Cat# 11130051), 2 mM L-glutamine (Corning, NY, Cat# 34717007), and 1% (v/v) penicillin/streptomycin (Gibco, Cat# 15140-122). All cells were tested negative for mycoplasma. Adult mouse DRG neurons were prepared from 8- to 12-week-old C57BL/6J using enzymatic dissociation.</p></sec><sec id="s4-3"><title>Viral vectors</title><p>MFN2 mutants and FRET probes were generated using PCR mutagenesis, sequence verified, and sent to Vector BioLabs for custom adenovirus production. Ad-CMV-β-Gal was purchased from Vector BioLabs (Cat# 1080).</p></sec><sec id="s4-4"><title>Protein structure modeling</title><p>Hypothetical structures of human MFN2 were generated using I-TASSER and Chimera UCSF. The putative closed conformation is based on structural homology with bacterial dynamin-like protein (PDB: 2J69). The Mfn2 open conformation was downloaded from the AlphaFold protein structure database (AF-095140-F1). Domain coloring is as follows: green GTPase (AA 94-265); red HR1 (AA 338-421); and blue HR-2 (AA 681-757).</p></sec><sec id="s4-5"><title>Imaging</title><p>Live cell studies of MEFs, H9c2 cells, or DRGs to assess mitochondrial morphology, respiratory function, mitophagy, and motility, and transmission electron microscopy studies were performed as previously described (<xref ref-type="bibr" rid="bib22">Franco et al., 2016</xref>; <xref ref-type="bibr" rid="bib10">Chen and Dorn, 2013</xref>; <xref ref-type="bibr" rid="bib41">Misko et al., 2010</xref> and <xref ref-type="bibr" rid="bib46">Rocha et al., 2018</xref>). Briefly, confocal fluorescence microscopy was used to gauge mitochondrial aspect ratio (length/width) quantified based on MitoTracker Green staining using ImageJ; mitochondrial depolarization quantified as the number of green/total mitochondria in MitoTracker Green/TMRE double-stained images; mitochondrial Parkin aggregation quantified in cells expressing mcParkin with or without MitoTracker green; mitolysosome formation quantified as number of red dots per cell in Mito QC-stained images; mitochondrial engulfment by autophagosomes quantified as the ratio of yellow to total cells (green/red overlay) in cells expressing LC3-GFP and co-stained with MitoTracker Orange. Mitochondrial motility was assessed in processes of cultured mouse DRG neurons expressing mitochondrial targeted RFP using time-lapse confocal microscopy (1 frame/5 s).</p><p><italic>Whole mouse embryos or adult mouse hearts</italic> were fixed with 4% formaldehyde solution in PBS, embedded in paraffin, and stained with hematoxylin-eosin (Sigma, GHS116 and HT110116) or TUNEL labeled using the manufacturer’s protocol (Promega, G3250).</p><p>Transmission electron microscopy of mouse heart tissues fixed in 4% paraformaldehyde, 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer, pH 7.4, used thin sections stained with osmium tetroxide/uranyl acetate. A JEOL electron microscope (JEM-1400, JEOL, Tokyo, Japan) at 1500×–5000× direct magnification was used for image acquisition. Mitochondrial size and surface density were quantified using ImageJ (NIH).</p></sec><sec id="s4-6"><title>Western blotting</title><p>Seventy-two hours after adenoviral transduction (MOI 50) with MFN2 mutants, Mfn1/Mfn2 DKO MEFs and H9c2 were pelleted and lysed in cell extraction buffer on ice (Thermo Fisher Scientific, Cat# FNN0011) with 1 mM PMSF, protease inhibitor (Roche, Cat# 05892970001) and phosphatase inhibitor (Roche, Cat# 04906837001). Primary antibodies used were anti-Mfn2 (1:500, Abcam ab56889) and anti-β-actin (1:3000, Proteintech, Cat# 66009-1). Horseradish peroxidase (HRP)-conjugated anti-mouse IgG (1:3000, cs7076) was from Cell Signaling Technology.</p></sec><sec id="s4-7"><title>GTPase activity assay</title><p><italic>Mfn1/Mfn2</italic> double-null MEFs were transduced with ad-MFN2 mutants (MOI 50). Mitochondria were isolated as described (<xref ref-type="bibr" rid="bib12">Dang et al., 2022</xref>; <xref ref-type="bibr" rid="bib11">Dang et al., 2020</xref>; <xref ref-type="bibr" rid="bib13">Detmer and Chan, 2007</xref>; <xref ref-type="bibr" rid="bib14">Dhingra et al., 2014</xref>), prepared on ice, and used fresh. Then, 100 μg of mitochondrial protein in triplicate was incubated in GTPase Buffer (Promega #V7681; Madison, WI) with 10 μM GTP and 1 mM DTT. Also, 1 μM MiM 111, 1 μM Chimera or DMSO (vehicle) were added as indicated and the reactants incubated at room temperature for 90 min in 96-well plates. The Promega GTPase-Glo assay kit was used to measure GTPase activity following the manufacturer’s instructions. Luminescence was quantified on a Promega GloMax Luminometer.</p></sec><sec id="s4-8"><title>MFN2 FRET assays</title><p>Mfn1/Mfn2 double-null MEFs were transduced with FRET ad-MFNs. Then, 72 hr later mitochondria were isolated and FRET measured in a 96-well format as described (<xref ref-type="bibr" rid="bib11">Dang et al., 2020</xref>).</p></sec><sec id="s4-9"><title>Mitochondrial respiration</title><p>Oxygen consumption rate (OCR) of mitofusin mutants expressed using adenoviral transduction of Mfn DKO MEFs or H9c2 cardiomyoblasts used a Seahorse XFe24 Extracellular Flux Analyzer (Seahorse Bioscience, Billerica, MA). Briefly, cells were plated on Seahorse XF24-well cell culture microplates for OCR measurements 72 hr after adenoviral transduction. Sensor cartridge hydration was performed overnight at 37°C. After basal respiration measurements, the following were autoinjected in sequence: 1 μM oligomycin to inhibit ATP synthase, 1 μM FCCP to uncouple oxidative phosphorylation, and 0.5 μM rotenone/antimycin A to abrogate electron transport (non-mitochondrial OCR). Each experiment averaged five or more replicate wells, and each experiment was repeated with a minimum of four biological replicates. ATP-linked respiration is basal OCR–OCR after oligomycin injection. Maximal mitochondrial respiration is OCR after FCCP–OCR after rotenone/antimycin A.</p></sec><sec id="s4-10"><title>Flow cytometry of mitochondrial ROS production</title><p>H9C2 cardiomyoblasts were transduced with adenoviral MFN2 constructs as described. Then, 72 hr later cells were co-stained with MitoSOX Red (5 μM for 10 min at 37°C) and MitoTracker Green FM 200 nM (Thermo Fisher, Cat# M36008 and #M7514, respectively). Fluorescence was analyzed on a ZE5 Flow Cytometer (Bio-Rad). Data were analyzed with FlowJo software version 10 and are presented as mean fluorescence intensity of five independent experiments.</p></sec><sec id="s4-11"><title>Creation of Mfn2 Q400 knock-in mice using Crisp/Cas9</title><p>The knock-in strategy is schematically depicted in <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>. CRISPR gRNAs for in vitro testing were identified using <ext-link ext-link-type="uri" xlink:href="http://crispr.mit.edu/">http://crispr.mit.edu/</ext-link>. Mfn2 sgRNA was cloned into BbsI digested plasmid pX330 (Addgene # 42230). sgRNA activity was validated in vitro by transfection of NIH3T3 cells using ROCHE Xtremegene HP. Cell pools were harvested 48 hr later for genomic DNA prep, followed by Sanger sequencing of products spanning the gRNA/Cas9 cleavage site and TIDE analysis (<ext-link ext-link-type="uri" xlink:href="https://tide.nki.nl/">https://tide.nki.nl/</ext-link>) of sequence trace files. T7 sgRNA template was PCR-amplified, gel-purified, and in vitro-transcribed with the MEGAshortscript T7 kit (Life Technologies). T7 Cas9 template was PCR-amplified, gel-purified, and in vitro-transcribed with the T7 mMessage mMachine Ultra kit (Life Technologies). After transcription, RNA was purified with Megaclear kit (Life Technologies). A 200 nt ssODN donor DNA with the mutation centered within the oligo was ordered from IDT as an ultramer oligo. Injection concentrations were 50 ng/μl Cas9, 25 ng/μl gRNA, and 20 ng/μl ssODN. Founders were identified using QIAGEN pyrosequencer and Pyromark Q96 2.5.7 software. All animal experiments were approved by institutional IACUC protocols. B6/CBA F1 mice at 3–4 wk of age (JAX Laboratories, Bar Harbor, ME) were superovulated by intraperitoneal injection of 5 IU pregnant mare serum gonadotropin, followed 48 hr later by intraperitoneal injection of 5 IU human chorionic gonadotropin (PMS from Sigma, HGC from Millipore USA). Mouse zygotes were obtained by mating B6/CBA stud males with superovulated B6/CBA females at a 1:1 ratio. Single-cell fertilized embryos were injected into the pronucleus and cytoplasm of each zygote using standard techniques.</p><list list-type="bullet"><list-item><p>gRNA sequence: 5′ <named-content content-type="sequence">AAGAGCGGCAAGACCgGCTG</named-content> 3</p></list-item><list-item><p>Antisense ssODN sequence: 5<named-content content-type="sequence">′cttcattctcacCTGCCTTTCCACTTCCTCCGTAATCTGCTTAATTCGCAGCTTGTAGTCTTGAGCCAGGAGCTCCAGCTGCTTGTCAATAAACCTCAGCtGGTCTTGCCGCTCTTCCCGCATTTCTAGGCAATAAACCctgagaggacaaaagcactgcttagaaacccgtgtccccacaagagcaagcagagaagcca</named-content> 3′</p></list-item></list></sec><sec id="s4-12"><title>Creation of Mfn2 T105M and M376V knock-in mice</title><p>CRISPR engineering was also performed at Cyagen, Inc to insert two CMT2A-associated mutations into the mouse genome. The overall procedures are similar to that described above.</p><p><italic>For Mfn2 T105M</italic>: gRNA (forward strand) sequence was 5′ <named-content content-type="sequence">TTTCATCCTAGGACGAGCAATGG</named-content> 3′. The p.T105M (ACG to ATG) in the donor oligo (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>) was introduced into exon 6 by homology-directed repair. Two synonymous mutations, p.S106 (AGC to TCA) and p.S110 (AGC to TCG), were introduced simultaneously to prevent the binding and recutting of the sequence by gRNA after homology-directed repair; the SalI restriction site was used for genotyping.</p><p>For <italic>Mfn2 M376V</italic>: gRNA (forward strand) sequence was 5′ <named-content content-type="sequence">CTCCTGAGCTGCGATGTGCAGGG</named-content> 3′. The p.M376V (ATG to GTG) in the donor oligo (see <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1C</xref>) was introduced into exon 12 by homology-directed repair. One synonymous mutation p.S378 (TCC to TCA) was also introduced to prevent the binding and recutting of the sequence by gRNA after homology-directed repair.</p><p>Pups were genotyped and correct integration of the fragment carrying the point mutation (p.T105M) or (p.M376V) was confirmed by Sanger sequencing. The correctly integrated mutant F0 founder mice were back-crossed with WT C57BL/6J mice to generate F1s. F1 heterozygous animals, also confirmed by Sanger sequencing, were interbred to build mouse colonies. All subsequent generation knock-mouse genotypes for all three lines were determined by Sanger sequencing.</p></sec><sec id="s4-13"><title>Omics studies</title><p>Total RNA from Mfn2Q/Q400 and C57BL/6J E.18.5 or P1 hearts was isolated using TRIzol Reagent (Cat# 15596-026, Ambion RNA Life Technologies) and treated with DNase I (Invitrogen, Cat# 18068015). mRNA library preparation and sequencing were performed at the Genome Technology Access Center (GTAC) of Washington University St. Louis, MO (USA) using the RiboErase protocol with indexing and pooled sequencing on a NovaSeq S4. Sequencing depth was 30M reads per sample. RNA-seq reads were aligned to the <italic>Mus musculus</italic> mm-10 assembly with STAR. Refseq was used as annotation model to quantify gene counts normalized to counts per million (CPM). Pair-wise comparisons between transcriptomic profiles from each experimental group were analyzed using GSA in Partek Flow and filtered a priori CPM ≥ 10 for at least one biological sample, FDR &lt; 0.05, p-value&lt;0.02, fold change &gt;2, &lt;-2. Unsupervised hierarchical clustering using Euclidean distance and average distance was performed using Partek Flow. KEGG Pathway analyses used Database for Annotation, Visualization and Integrated Discovery (DAVID v6.8). The GEO accession number is GSE214984.</p><p>Metabolomics analyses of acylcarnitines, organic acids, and amino acids in P0 hearts were performed as described (<xref ref-type="bibr" rid="bib25">Gong et al., 2015</xref>).</p></sec><sec id="s4-14"><title>Doxorubicin experiments</title><p>In vitro – H9c2 cells were transduced with adenovirus encoding MFN2 R400 (WT) or Q400 at 100 MOI 48 hr prior to addition of doxorubicin; immunoblotting confirmed equal levels of MFN2 expression. MFN2-expressing cells were cultured in the presence of increasing doxorubicin concentrations (0.1–50 uM), or in the concentration specified, for 1, 12, or 24 hr as indicated. Live-dead staining used the kit from Invitrogen (Cat# L3224). TUNEL labeling used the DeadEnd Fluorometric kit from Promega (Cat# G3250). Mito QC mitolysosome labeling and mc Parkin aggregation studies are described above.</p><p>In vivo – 8–10-week-old male WT (R/R400), heterozygous (R/Q400 knock-in), and homozygous (Q/Q400 knock-in) mice underwent baseline echocardiographic assessments prior to receiving a single dose of doxorubicin (20 ug/g via intraperitoneal injection; <xref ref-type="bibr" rid="bib14">Dhingra et al., 2014</xref>). Four days later, each mouse was administered adenovirus-Mito QC (3.3 × 10<sup>11</sup> particles in 100 ul). Echocardiography was performed 4 and 7 d post doxorubicin; mice were terminated after the 7-day echo study. Hearts were dissected, removed, placed in ice-cold physiological saline (0.9% NaCl), and weighed; heart weights were indexed to tibial length to account for individual variations in weight loss induced by doxorubicin. Mito QC staining was evaluated by confocal fluorescence imaging in 12 um frozen sections of OCT-embedded specimens.</p></sec><sec id="s4-15"><title>Data presentation and statistical analyses</title><p>Data are reported as means ± SEM. Sample number (n) indicates the number of independent biological samples. Two-group comparisons used Student’s <italic>t</italic>-test; multiple group comparisons used one-way ANOVA with Tukey’s post hoc test for individual statistical comparisons. Survival was evaluated by Kaplan–Meier analysis and the log-rank (Mantel–Cox) test. Comparisons of population MAF used chi-square testing. p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Resources, Data curation, Formal analysis, Validation, Investigation, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Resources, Formal analysis, Validation, Investigation</p></fn><fn fn-type="con" id="con3"><p>Resources, Data curation, Validation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Resources, Data curation, Validation</p></fn><fn fn-type="con" id="con5"><p>Data curation, Validation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con7"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Validation, Investigation</p></fn><fn fn-type="con" id="con10"><p>Validation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Formal analysis</p></fn><fn fn-type="con" id="con12"><p>Methodology</p></fn><fn fn-type="con" id="con13"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All experimental procedures were approved by the Washington University in St. Louis, School of Medicine Animal Studies Committee; IACUC protocol number 22-0314 Exp:12/27/2025, .PI Gerald Dorn.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-84235-mdarchecklist1-v1.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Sequencing Data have been deposited in GEO under accession code GSE214984. - The putative closed conformation is based on structural homology with bacterial dynamin-like protein (PDB: 2J69). The Mfn2 open conformation was downloaded from the AlphaFold protein structure database (AF-095140-F1).</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2023">2023</year><data-title>A human mitofusin 2 mutation can cause mitophagic cardiomyopathy</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE214984">GSE214984</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>GWD conceived of and designed the research. GWD and AF wrote the manuscript. AF and JL performed mitochondrial function, GTPase and FRET assays, and knock-in mouse studies. RML and MS generated the CRISPR/Cas9 knock-in mouse. DPK and the Sanford-Burnham Medical Discovery Institute Metabolomics Core performed and analyzed the metabolomics studies. CdGS, MEM, ADS, AF JE, and XD analyzed RNAseq or human <italic>MFN2</italic> genotype data. RH, AJM, and GWD provided human <italic>MFN2</italic> sequencing from cardiomyopathy research cohorts. JE analyzed RNAseq in revised manuscript. All authors agree with their inclusion and place in the author list.</p><p>Supported by NIH R35 HL135736, R42 NS115184 and R42 NS113642 to GWD, R01 HL128349 to DPK, and by the Hope Center Transgenic Vectors Core at Washington University School of Medicine.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aronow</surname><given-names>BJ</given-names></name><name><surname>Toyokawa</surname><given-names>T</given-names></name><name><surname>Canning</surname><given-names>A</given-names></name><name><surname>Haghighi</surname><given-names>K</given-names></name><name><surname>Delling</surname><given-names>U</given-names></name><name><surname>Kranias</surname><given-names>E</given-names></name><name><surname>Molkentin</surname><given-names>JD</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy</article-title><source>Physiological Genomics</source><volume>6</volume><fpage>19</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1152/physiolgenomics.2001.6.1.19</pub-id><pub-id pub-id-type="pmid">11395543</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Auer</surname><given-names>PL</given-names></name><name><surname>Lettre</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Rare variant association studies: considerations, challenges and opportunities</article-title><source>Genome Medicine</source><volume>7</volume><elocation-id>16</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-015-0138-2</pub-id><pub-id pub-id-type="pmid">25709717</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhandari</surname><given-names>P</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Burelle</surname><given-names>Y</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Mitochondrial contagion induced by Parkin deficiency in <italic>Drosophila</italic> hearts and its containment by suppressing mitofusin</article-title><source>Circulation Research</source><volume>114</volume><fpage>257</fpage><lpage>265</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302734</pub-id><pub-id pub-id-type="pmid">24192653</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bomba</surname><given-names>L</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The impact of rare and low-frequency genetic variants in common disease</article-title><source>Genome Biology</source><volume>18</volume><elocation-id>77</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-017-1212-4</pub-id><pub-id pub-id-type="pmid">28449691</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cappola</surname><given-names>TP</given-names></name><name><surname>Matkovich</surname><given-names>SJ</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>van Booven</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>L</given-names></name><name><surname>Sweitzer</surname><given-names>NK</given-names></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Reilly</surname><given-names>MP</given-names></name><name><surname>Hakonarson</surname><given-names>H</given-names></name><name><surname>Nerbonne</surname><given-names>JM</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Loss-of-function DNA sequence variant in the CLCNKA chloride channel implicates the cardio-renal axis in interindividual heart failure risk variation</article-title><source>PNAS</source><volume>108</volume><fpage>2456</fpage><lpage>2461</lpage><pub-id pub-id-type="doi">10.1073/pnas.1017494108</pub-id><pub-id pub-id-type="pmid">21248228</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mitochondrial fusion and fission in mammals</article-title><source>Annual Review of Cell and Developmental Biology</source><volume>22</volume><fpage>79</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1146/annurev.cellbio.22.010305.104638</pub-id><pub-id pub-id-type="pmid">16704336</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Detmer</surname><given-names>SA</given-names></name><name><surname>Ewald</surname><given-names>AJ</given-names></name><name><surname>Griffin</surname><given-names>EE</given-names></name><name><surname>Fraser</surname><given-names>SE</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Mitofusins Mfn1 and Mfn2 coordinately regulate mitochondrial fusion and are essential for embryonic development</article-title><source>The Journal of Cell Biology</source><volume>160</volume><fpage>189</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1083/jcb.200211046</pub-id><pub-id pub-id-type="pmid">12527753</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Vermulst</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>YE</given-names></name><name><surname>Chomyn</surname><given-names>A</given-names></name><name><surname>Prolla</surname><given-names>TA</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mitochondrial fusion is required for mtDNA stability in skeletal muscle and tolerance of mtDNA mutations</article-title><source>Cell</source><volume>141</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.02.026</pub-id><pub-id pub-id-type="pmid">20403324</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Mitochondrial fusion is essential for organelle function and cardiac homeostasis</article-title><source>Circulation Research</source><volume>109</volume><fpage>1327</fpage><lpage>1331</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.258723</pub-id><pub-id pub-id-type="pmid">22052916</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>PINK1-phosphorylated mitofusin 2 is a Parkin receptor for culling damaged mitochondria</article-title><source>Science</source><volume>340</volume><fpage>471</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1126/science.1231031</pub-id><pub-id pub-id-type="pmid">23620051</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Rocha</surname><given-names>AG</given-names></name><name><surname>Devanathan</surname><given-names>S</given-names></name><name><surname>Dolle</surname><given-names>RE</given-names></name><name><surname>Bernstein</surname><given-names>PR</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Discovery of 6-Phenylhexanamide Derivatives as Potent Stereoselective Mitofusin Activators for the Treatment of Mitochondrial Diseases</article-title><source>Journal of Medicinal Chemistry</source><volume>63</volume><fpage>7033</fpage><lpage>7051</lpage><pub-id pub-id-type="doi">10.1021/acs.jmedchem.0c00366</pub-id><pub-id pub-id-type="pmid">32506913</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Walton</surname><given-names>EK</given-names></name><name><surname>Zablocka</surname><given-names>B</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name><name><surname>Shy</surname><given-names>ME</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial phenotypes in genetically diverse neurodegenerative diseases and their response to mitofusin activation</article-title><source>Cells</source><volume>11</volume><elocation-id>1053</elocation-id><pub-id pub-id-type="doi">10.3390/cells11061053</pub-id><pub-id pub-id-type="pmid">35326504</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Detmer</surname><given-names>SA</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Complementation between mouse Mfn1 and Mfn2 protects mitochondrial fusion defects caused by CMT2A disease mutations</article-title><source>The Journal of Cell Biology</source><volume>176</volume><fpage>405</fpage><lpage>414</lpage><pub-id pub-id-type="doi">10.1083/jcb.200611080</pub-id><pub-id pub-id-type="pmid">17296794</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhingra</surname><given-names>R</given-names></name><name><surname>Margulets</surname><given-names>V</given-names></name><name><surname>Chowdhury</surname><given-names>SR</given-names></name><name><surname>Thliveris</surname><given-names>J</given-names></name><name><surname>Jassal</surname><given-names>D</given-names></name><name><surname>Fernyhough</surname><given-names>P</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Kirshenbaum</surname><given-names>LA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Bnip3 mediates doxorubicin-induced cardiac myocyte necrosis and mortality through changes in mitochondrial signaling</article-title><source>PNAS</source><volume>111</volume><fpage>E5537</fpage><lpage>E5544</lpage><pub-id pub-id-type="doi">10.1073/pnas.1414665111</pub-id><pub-id pub-id-type="pmid">25489073</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Parkin-dependent mitophagy in the heart</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>95</volume><fpage>42</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2015.11.023</pub-id><pub-id pub-id-type="pmid">26611886</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Evolving concepts of mitochondrial dynamics</article-title><source>Annual Review of Physiology</source><volume>81</volume><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-020518-114358</pub-id><pub-id pub-id-type="pmid">30256725</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitofusins as mitochondrial anchors and tethers</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>142</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2020.04.016</pub-id><pub-id pub-id-type="pmid">32304672</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Mitofusin activation enhances mitochondrial motility and promotes neuroregeneration in CMT2A</article-title><source>Neural Regeneration Research</source><volume>16</volume><fpage>2201</fpage><lpage>2203</lpage><pub-id pub-id-type="doi">10.4103/1673-5374.310684</pub-id><pub-id pub-id-type="pmid">33818493</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Predicting mitochondrial dynamic behavior in genetically defined neurodegenerative diseases</article-title><source>Cells</source><volume>11</volume><elocation-id>1049</elocation-id><pub-id pub-id-type="doi">10.3390/cells11061049</pub-id><pub-id pub-id-type="pmid">35326500</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschenbacher</surname><given-names>WH</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Bhandari</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name><name><surname>Jowdy</surname><given-names>CC</given-names></name><name><surname>Engelhard</surname><given-names>JT</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Two rare human mitofusin 2 mutations alter mitochondrial dynamics and induce retinal and cardiac pathology in <italic>Drosophila</italic></article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e44296</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0044296</pub-id><pub-id pub-id-type="pmid">22957060</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flannick</surname><given-names>J</given-names></name><name><surname>Thorleifsson</surname><given-names>G</given-names></name><name><surname>Beer</surname><given-names>NL</given-names></name><name><surname>Jacobs</surname><given-names>SBR</given-names></name><name><surname>Grarup</surname><given-names>N</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Fuchsberger</surname><given-names>C</given-names></name><name><surname>Atzmon</surname><given-names>G</given-names></name><name><surname>Benediktsson</surname><given-names>R</given-names></name><name><surname>Blangero</surname><given-names>J</given-names></name><name><surname>Bowden</surname><given-names>DW</given-names></name><name><surname>Brandslund</surname><given-names>I</given-names></name><name><surname>Brosnan</surname><given-names>J</given-names></name><name><surname>Burslem</surname><given-names>F</given-names></name><name><surname>Chambers</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Christensen</surname><given-names>C</given-names></name><name><surname>Douglas</surname><given-names>DA</given-names></name><name><surname>Duggirala</surname><given-names>R</given-names></name><name><surname>Dymek</surname><given-names>Z</given-names></name><name><surname>Farjoun</surname><given-names>Y</given-names></name><name><surname>Fennell</surname><given-names>T</given-names></name><name><surname>Fontanillas</surname><given-names>P</given-names></name><name><surname>Forsén</surname><given-names>T</given-names></name><name><surname>Gabriel</surname><given-names>S</given-names></name><name><surname>Glaser</surname><given-names>B</given-names></name><name><surname>Gudbjartsson</surname><given-names>DF</given-names></name><name><surname>Hanis</surname><given-names>C</given-names></name><name><surname>Hansen</surname><given-names>T</given-names></name><name><surname>Hreidarsson</surname><given-names>AB</given-names></name><name><surname>Hveem</surname><given-names>K</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Isomaa</surname><given-names>B</given-names></name><name><surname>Johansson</surname><given-names>S</given-names></name><name><surname>Jørgensen</surname><given-names>T</given-names></name><name><surname>Jørgensen</surname><given-names>ME</given-names></name><name><surname>Kathiresan</surname><given-names>S</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Kooner</surname><given-names>J</given-names></name><name><surname>Kravic</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>J-Y</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Linneberg</surname><given-names>A</given-names></name><name><surname>Masson</surname><given-names>G</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Mohlke</surname><given-names>KL</given-names></name><name><surname>Molven</surname><given-names>A</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Potluri</surname><given-names>S</given-names></name><name><surname>Rauramaa</surname><given-names>R</given-names></name><name><surname>Ribel-Madsen</surname><given-names>R</given-names></name><name><surname>Richard</surname><given-names>A-M</given-names></name><name><surname>Rolph</surname><given-names>T</given-names></name><name><surname>Salomaa</surname><given-names>V</given-names></name><name><surname>Segrè</surname><given-names>AV</given-names></name><name><surname>Skärstrand</surname><given-names>H</given-names></name><name><surname>Steinthorsdottir</surname><given-names>V</given-names></name><name><surname>Stringham</surname><given-names>HM</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Teo</surname><given-names>YY</given-names></name><name><surname>Teslovich</surname><given-names>T</given-names></name><name><surname>Thorsteinsdottir</surname><given-names>U</given-names></name><name><surname>Trimmer</surname><given-names>JK</given-names></name><name><surname>Tuomi</surname><given-names>T</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Vaziri-Sani</surname><given-names>F</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Njølstad</surname><given-names>PR</given-names></name><name><surname>Pedersen</surname><given-names>O</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Cox</surname><given-names>DR</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name><name><surname>Altshuler</surname><given-names>D</given-names></name><collab>Go-T2D Consortium</collab><collab>T2D-GENES Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Loss-of-function mutations in SLC30A8 protect against type 2 diabetes</article-title><source>Nature Genetics</source><volume>46</volume><fpage>357</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1038/ng.2915</pub-id><pub-id pub-id-type="pmid">24584071</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Kitsis</surname><given-names>RN</given-names></name><name><surname>Fleischer</surname><given-names>JA</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Kornfeld</surname><given-names>OS</given-names></name><name><surname>Gong</surname><given-names>G</given-names></name><name><surname>Biris</surname><given-names>N</given-names></name><name><surname>Benz</surname><given-names>A</given-names></name><name><surname>Qvit</surname><given-names>N</given-names></name><name><surname>Donnelly</surname><given-names>SK</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Mennerick</surname><given-names>S</given-names></name><name><surname>Hodgson</surname><given-names>L</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Correcting mitochondrial fusion by manipulating mitofusin conformations</article-title><source>Nature</source><volume>540</volume><fpage>74</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1038/nature20156</pub-id><pub-id pub-id-type="pmid">27775718</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Walton</surname><given-names>EK</given-names></name><name><surname>Ho</surname><given-names>JN</given-names></name><name><surname>Zablocka</surname><given-names>B</given-names></name><name><surname>Ly</surname><given-names>C</given-names></name><name><surname>Miller</surname><given-names>TM</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name><name><surname>Shy</surname><given-names>ME</given-names></name><name><surname>Yoo</surname><given-names>AS</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Burst mitofusin activation reverses neuromuscular dysfunction in murine CMT2A</article-title><source>eLife</source><volume>9</volume><elocation-id>e61119</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.61119</pub-id><pub-id pub-id-type="pmid">33074106</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Molinoff</surname><given-names>PB</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondrial Dysfunction and Pharmacodynamics of Mitofusin Activation in Murine Charcot-Marie-Tooth Disease Type 2A</article-title><source>The Journal of Pharmacology and Experimental Therapeutics</source><volume>383</volume><fpage>137</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1124/jpet.122.001332</pub-id><pub-id pub-id-type="pmid">36507849</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Csordas</surname><given-names>G</given-names></name><name><surname>Kelly</surname><given-names>DP</given-names></name><name><surname>Matkovich</surname><given-names>SJ</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation in mice</article-title><source>Science</source><volume>350</volume><elocation-id>aad2459</elocation-id><pub-id pub-id-type="doi">10.1126/science.aad2459</pub-id><pub-id pub-id-type="pmid">26785495</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hescheler</surname><given-names>J</given-names></name><name><surname>Meyer</surname><given-names>R</given-names></name><name><surname>Plant</surname><given-names>S</given-names></name><name><surname>Krautwurst</surname><given-names>D</given-names></name><name><surname>Rosenthal</surname><given-names>W</given-names></name><name><surname>Schultz</surname><given-names>G</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>Morphological, biochemical, and electrophysiological characterization of a clonal cell (H9c2) line from rat heart</article-title><source>Circulation Research</source><volume>69</volume><fpage>1476</fpage><lpage>1486</lpage><pub-id pub-id-type="doi">10.1161/01.res.69.6.1476</pub-id><pub-id pub-id-type="pmid">1683272</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>YHR</given-names></name><name><surname>Yogasundaram</surname><given-names>H</given-names></name><name><surname>Parajuli</surname><given-names>N</given-names></name><name><surname>Valtuille</surname><given-names>L</given-names></name><name><surname>Sergi</surname><given-names>C</given-names></name><name><surname>Oudit</surname><given-names>GY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MELAS syndrome and cardiomyopathy: linking mitochondrial function to heart failure pathogenesis</article-title><source>Heart Failure Reviews</source><volume>21</volume><fpage>103</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1007/s10741-015-9524-5</pub-id><pub-id pub-id-type="pmid">26712328</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huggins</surname><given-names>GS</given-names></name><name><surname>Kinnamon</surname><given-names>DD</given-names></name><name><surname>Haas</surname><given-names>GJ</given-names></name><name><surname>Jordan</surname><given-names>E</given-names></name><name><surname>Hofmeyer</surname><given-names>M</given-names></name><name><surname>Kransdorf</surname><given-names>E</given-names></name><name><surname>Ewald</surname><given-names>GA</given-names></name><name><surname>Morris</surname><given-names>AA</given-names></name><name><surname>Owens</surname><given-names>A</given-names></name><name><surname>Lowes</surname><given-names>B</given-names></name><name><surname>Stoller</surname><given-names>D</given-names></name><name><surname>Tang</surname><given-names>WHW</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Trachtenberg</surname><given-names>BH</given-names></name><name><surname>Shah</surname><given-names>P</given-names></name><name><surname>Pamboukian</surname><given-names>SV</given-names></name><name><surname>Sweitzer</surname><given-names>NK</given-names></name><name><surname>Wheeler</surname><given-names>MT</given-names></name><name><surname>Wilcox</surname><given-names>JE</given-names></name><name><surname>Katz</surname><given-names>S</given-names></name><name><surname>Pan</surname><given-names>S</given-names></name><name><surname>Jimenez</surname><given-names>J</given-names></name><name><surname>Aaronson</surname><given-names>KD</given-names></name><name><surname>Fishbein</surname><given-names>DP</given-names></name><name><surname>Smart</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Gottlieb</surname><given-names>SS</given-names></name><name><surname>Judge</surname><given-names>DP</given-names></name><name><surname>Moore</surname><given-names>CK</given-names></name><name><surname>Mead</surname><given-names>JO</given-names></name><name><surname>Ni</surname><given-names>H</given-names></name><name><surname>Burke</surname><given-names>W</given-names></name><name><surname>Hershberger</surname><given-names>RE</given-names></name><collab>DCM Precision Medicine Study of the DCM Consortium</collab></person-group><year iso-8601-date="2022">2022</year><article-title>Prevalence and cumulative risk of familial idiopathic dilated cardiomyopathy</article-title><source>JAMA</source><volume>327</volume><fpage>454</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.24674</pub-id><pub-id pub-id-type="pmid">35103767</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>WT</given-names></name><name><surname>Giddings</surname><given-names>TH</given-names></name><name><surname>Taylor</surname><given-names>MP</given-names></name><name><surname>Mulinyawe</surname><given-names>S</given-names></name><name><surname>Rabinovitch</surname><given-names>M</given-names></name><name><surname>Kopito</surname><given-names>RR</given-names></name><name><surname>Kirkegaard</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Subversion of cellular autophagosomal machinery by RNA viruses</article-title><source>PLOS Biology</source><volume>3</volume><elocation-id>e156</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pbio.0030156</pub-id><pub-id pub-id-type="pmid">15884975</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>A</given-names></name><name><surname>Cipolat</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Mitochondrial fusion directs cardiomyocyte differentiation via calcineurin and Notch signaling</article-title><source>Science</source><volume>342</volume><fpage>734</fpage><lpage>737</lpage><pub-id pub-id-type="doi">10.1126/science.1241359</pub-id><pub-id pub-id-type="pmid">24091702</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kuznetsov</surname><given-names>AV</given-names></name><name><surname>Javadov</surname><given-names>S</given-names></name><name><surname>Sickinger</surname><given-names>S</given-names></name><name><surname>Frotschnig</surname><given-names>S</given-names></name><name><surname>Grimm</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>H9c2 and HL-1 cells demonstrate distinct features of energy metabolism, mitochondrial function and sensitivity to hypoxia-reoxygenation</article-title><source>Biochimica et Biophysica Acta</source><volume>1853</volume><fpage>276</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.11.015</pub-id><pub-id pub-id-type="pmid">25450968</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Bainbridge</surname><given-names>MN</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Marian</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>A potential oligogenic etiology of hypertrophic cardiomyopathy: A classic single-gene disorder</article-title><source>Circulation Research</source><volume>120</volume><fpage>1084</fpage><lpage>1090</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.310559</pub-id><pub-id pub-id-type="pmid">28223422</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YJ</given-names></name><name><surname>Cao</surname><given-names>YL</given-names></name><name><surname>Feng</surname><given-names>JX</given-names></name><name><surname>Qi</surname><given-names>Y</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>JF</given-names></name><name><surname>Zhong</surname><given-names>YT</given-names></name><name><surname>Kang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Lan</surname><given-names>L</given-names></name><name><surname>Luo</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chan</surname><given-names>DC</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Structural insights of human mitofusin-2 into mitochondrial fusion and CMT2A onset</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>4914</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12912-0</pub-id><pub-id pub-id-type="pmid">31664033</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Dang</surname><given-names>X</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Reciprocal Regulation of Mitofusin 2-Mediated Mitophagy and Mitochondrial Fusion by Different PINK1 Phosphorylation Events</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>10</volume><elocation-id>868465</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.868465</pub-id><pub-id pub-id-type="pmid">35646911</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liggett</surname><given-names>SB</given-names></name><name><surname>Cresci</surname><given-names>S</given-names></name><name><surname>Kelly</surname><given-names>RJ</given-names></name><name><surname>Syed</surname><given-names>FM</given-names></name><name><surname>Matkovich</surname><given-names>SJ</given-names></name><name><surname>Hahn</surname><given-names>HS</given-names></name><name><surname>Diwan</surname><given-names>A</given-names></name><name><surname>Martini</surname><given-names>JS</given-names></name><name><surname>Sparks</surname><given-names>L</given-names></name><name><surname>Parekh</surname><given-names>RR</given-names></name><name><surname>Spertus</surname><given-names>JA</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name><name><surname>Kardia</surname><given-names>SLR</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure</article-title><source>Nature Medicine</source><volume>14</volume><fpage>510</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/nm1750</pub-id><pub-id pub-id-type="pmid">18425130</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lopaschuk</surname><given-names>GD</given-names></name><name><surname>Collins-Nakai</surname><given-names>RL</given-names></name><name><surname>Itoi</surname><given-names>T</given-names></name></person-group><year iso-8601-date="1992">1992</year><article-title>Developmental changes in energy substrate use by the heart</article-title><source>Cardiovascular Research</source><volume>26</volume><fpage>1172</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1093/cvr/26.12.1172</pub-id><pub-id pub-id-type="pmid">1288863</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacArthur</surname><given-names>DG</given-names></name><name><surname>Balasubramanian</surname><given-names>S</given-names></name><name><surname>Frankish</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>N</given-names></name><name><surname>Morris</surname><given-names>J</given-names></name><name><surname>Walter</surname><given-names>K</given-names></name><name><surname>Jostins</surname><given-names>L</given-names></name><name><surname>Habegger</surname><given-names>L</given-names></name><name><surname>Pickrell</surname><given-names>JK</given-names></name><name><surname>Montgomery</surname><given-names>SB</given-names></name><name><surname>Albers</surname><given-names>CA</given-names></name><name><surname>Zhang</surname><given-names>ZD</given-names></name><name><surname>Conrad</surname><given-names>DF</given-names></name><name><surname>Lunter</surname><given-names>G</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Ayub</surname><given-names>Q</given-names></name><name><surname>DePristo</surname><given-names>MA</given-names></name><name><surname>Banks</surname><given-names>E</given-names></name><name><surname>Hu</surname><given-names>M</given-names></name><name><surname>Handsaker</surname><given-names>RE</given-names></name><name><surname>Rosenfeld</surname><given-names>JA</given-names></name><name><surname>Fromer</surname><given-names>M</given-names></name><name><surname>Jin</surname><given-names>M</given-names></name><name><surname>Mu</surname><given-names>XJ</given-names></name><name><surname>Khurana</surname><given-names>E</given-names></name><name><surname>Ye</surname><given-names>K</given-names></name><name><surname>Kay</surname><given-names>M</given-names></name><name><surname>Saunders</surname><given-names>GI</given-names></name><name><surname>Suner</surname><given-names>MM</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Barnes</surname><given-names>IHA</given-names></name><name><surname>Amid</surname><given-names>C</given-names></name><name><surname>Carvalho-Silva</surname><given-names>DR</given-names></name><name><surname>Bignell</surname><given-names>AH</given-names></name><name><surname>Snow</surname><given-names>C</given-names></name><name><surname>Yngvadottir</surname><given-names>B</given-names></name><name><surname>Bumpstead</surname><given-names>S</given-names></name><name><surname>Cooper</surname><given-names>DN</given-names></name><name><surname>Xue</surname><given-names>Y</given-names></name><name><surname>Romero</surname><given-names>IG</given-names></name><collab>1000 Genomes Project Consortium</collab><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Gibbs</surname><given-names>RA</given-names></name><name><surname>McCarroll</surname><given-names>SA</given-names></name><name><surname>Dermitzakis</surname><given-names>ET</given-names></name><name><surname>Pritchard</surname><given-names>JK</given-names></name><name><surname>Barrett</surname><given-names>JC</given-names></name><name><surname>Harrow</surname><given-names>J</given-names></name><name><surname>Hurles</surname><given-names>ME</given-names></name><name><surname>Gerstein</surname><given-names>MB</given-names></name><name><surname>Tyler-Smith</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A systematic survey of loss-of-function variants in human protein-coding genes</article-title><source>Science</source><volume>335</volume><fpage>823</fpage><lpage>828</lpage><pub-id pub-id-type="doi">10.1126/science.1215040</pub-id><pub-id pub-id-type="pmid">22344438</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madeira</surname><given-names>VMC</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Overview of mitochondrial bioenergetics</article-title><source>Methods in Molecular Biology</source><volume>1782</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-7831-1_1</pub-id><pub-id pub-id-type="pmid">29850991</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matkovich</surname><given-names>SJ</given-names></name><name><surname>Van Booven</surname><given-names>DJ</given-names></name><name><surname>Cappola</surname><given-names>TP</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Association of an intronic, but not any exonic, FRMD4B sequence variant and heart failure</article-title><source>Clinical and Translational Science</source><volume>3</volume><fpage>134</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1111/j.1752-8062.2010.00220.x</pub-id><pub-id pub-id-type="pmid">20718813</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzarotto</surname><given-names>F</given-names></name><name><surname>Tayal</surname><given-names>U</given-names></name><name><surname>Buchan</surname><given-names>RJ</given-names></name><name><surname>Midwinter</surname><given-names>W</given-names></name><name><surname>Wilk</surname><given-names>A</given-names></name><name><surname>Whiffin</surname><given-names>N</given-names></name><name><surname>Govind</surname><given-names>R</given-names></name><name><surname>Mazaika</surname><given-names>E</given-names></name><name><surname>de Marvao</surname><given-names>A</given-names></name><name><surname>Dawes</surname><given-names>TJW</given-names></name><name><surname>Felkin</surname><given-names>LE</given-names></name><name><surname>Ahmad</surname><given-names>M</given-names></name><name><surname>Theotokis</surname><given-names>PI</given-names></name><name><surname>Edwards</surname><given-names>E</given-names></name><name><surname>Ing</surname><given-names>AY</given-names></name><name><surname>Thomson</surname><given-names>KL</given-names></name><name><surname>Chan</surname><given-names>LLH</given-names></name><name><surname>Sim</surname><given-names>D</given-names></name><name><surname>Baksi</surname><given-names>AJ</given-names></name><name><surname>Pantazis</surname><given-names>A</given-names></name><name><surname>Roberts</surname><given-names>AM</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Funke</surname><given-names>B</given-names></name><name><surname>O’Regan</surname><given-names>DP</given-names></name><name><surname>Olivotto</surname><given-names>I</given-names></name><name><surname>Barton</surname><given-names>PJR</given-names></name><name><surname>Prasad</surname><given-names>SK</given-names></name><name><surname>Cook</surname><given-names>SA</given-names></name><name><surname>Ware</surname><given-names>JS</given-names></name><name><surname>Walsh</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Reevaluating the genetic contribution of monogenic dilated cardiomyopathy</article-title><source>Circulation</source><volume>141</volume><fpage>387</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.037661</pub-id><pub-id pub-id-type="pmid">31983221</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Misko</surname><given-names>A</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Wegorzewska</surname><given-names>I</given-names></name><name><surname>Milbrandt</surname><given-names>J</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex</article-title><source>The Journal of Neuroscience</source><volume>30</volume><fpage>4232</fpage><lpage>4240</lpage><pub-id pub-id-type="doi">10.1523/JNEUROSCI.6248-09.2010</pub-id><pub-id pub-id-type="pmid">20335458</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Narendra</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Suen</surname><given-names>DF</given-names></name><name><surname>Youle</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Parkin is recruited selectively to impaired mitochondria and promotes their autophagy</article-title><source>The Journal of Cell Biology</source><volume>183</volume><fpage>795</fpage><lpage>803</lpage><pub-id pub-id-type="doi">10.1083/jcb.200809125</pub-id><pub-id pub-id-type="pmid">19029340</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ordureau</surname><given-names>A</given-names></name><name><surname>Sarraf</surname><given-names>SA</given-names></name><name><surname>Duda</surname><given-names>DM</given-names></name><name><surname>Heo</surname><given-names>JM</given-names></name><name><surname>Jedrychowski</surname><given-names>MP</given-names></name><name><surname>Sviderskiy</surname><given-names>VO</given-names></name><name><surname>Olszewski</surname><given-names>JL</given-names></name><name><surname>Koerber</surname><given-names>JT</given-names></name><name><surname>Xie</surname><given-names>T</given-names></name><name><surname>Beausoleil</surname><given-names>SA</given-names></name><name><surname>Wells</surname><given-names>JA</given-names></name><name><surname>Gygi</surname><given-names>SP</given-names></name><name><surname>Schulman</surname><given-names>BA</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quantitative proteomics reveal a feedforward mechanism for mitochondrial PARKIN translocation and ubiquitin chain synthesis</article-title><source>Molecular Cell</source><volume>56</volume><fpage>360</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.09.007</pub-id><pub-id pub-id-type="pmid">25284222</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Osio</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>SN</given-names></name><name><surname>Lombardi</surname><given-names>R</given-names></name><name><surname>Nagueh</surname><given-names>SF</given-names></name><name><surname>Shete</surname><given-names>S</given-names></name><name><surname>Roberts</surname><given-names>R</given-names></name><name><surname>Willerson</surname><given-names>JT</given-names></name><name><surname>Marian</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Myozenin 2 is a novel gene for human hypertrophic cardiomyopathy</article-title><source>Circulation Research</source><volume>100</volume><fpage>766</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000263008.66799.aa</pub-id><pub-id pub-id-type="pmid">17347475</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piquereau</surname><given-names>J</given-names></name><name><surname>Ventura-Clapier</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Maturation of cardiac energy metabolism during perinatal development</article-title><source>Frontiers in Physiology</source><volume>9</volume><elocation-id>959</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2018.00959</pub-id><pub-id pub-id-type="pmid">30072919</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rocha</surname><given-names>AG</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Krezel</surname><given-names>AM</given-names></name><name><surname>Rumsey</surname><given-names>JM</given-names></name><name><surname>Alberti</surname><given-names>JM</given-names></name><name><surname>Knight</surname><given-names>WC</given-names></name><name><surname>Biris</surname><given-names>N</given-names></name><name><surname>Zacharioudakis</surname><given-names>E</given-names></name><name><surname>Janetka</surname><given-names>JW</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name><name><surname>Kitsis</surname><given-names>RN</given-names></name><name><surname>Mochly-Rosen</surname><given-names>D</given-names></name><name><surname>Townsend</surname><given-names>RR</given-names></name><name><surname>Gavathiotis</surname><given-names>E</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>MFN2 agonists reverse mitochondrial defects in preclinical models of Charcot-Marie-Tooth disease type 2A</article-title><source>Science</source><volume>360</volume><fpage>336</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1126/science.aao1785</pub-id><pub-id pub-id-type="pmid">29674596</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santel</surname><given-names>A</given-names></name><name><surname>Fuller</surname><given-names>MT</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Control of mitochondrial morphology by a human mitofusin</article-title><source>Journal of Cell Science</source><volume>114</volume><fpage>867</fpage><lpage>874</lpage><pub-id pub-id-type="doi">10.1242/jcs.114.5.867</pub-id><pub-id pub-id-type="pmid">11181170</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schirone</surname><given-names>L</given-names></name><name><surname>D’Ambrosio</surname><given-names>L</given-names></name><name><surname>Forte</surname><given-names>M</given-names></name><name><surname>Genovese</surname><given-names>R</given-names></name><name><surname>Schiavon</surname><given-names>S</given-names></name><name><surname>Spinosa</surname><given-names>G</given-names></name><name><surname>Iacovone</surname><given-names>G</given-names></name><name><surname>Valenti</surname><given-names>V</given-names></name><name><surname>Frati</surname><given-names>G</given-names></name><name><surname>Sciarretta</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mitochondria and Doxorubicin-Induced Cardiomyopathy: A Complex Interplay</article-title><source>Cells</source><volume>11</volume><elocation-id>13</elocation-id><pub-id pub-id-type="doi">10.3390/cells11132000</pub-id><pub-id pub-id-type="pmid">35805084</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Mihara</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Scorrano</surname><given-names>L</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Mitochondrial fission and fusion factors reciprocally orchestrate mitophagic culling in mouse hearts and cultured fibroblasts</article-title><source>Cell Metabolism</source><volume>21</volume><fpage>273</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2014.12.011</pub-id><pub-id pub-id-type="pmid">25600785</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>M</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Fleischer</surname><given-names>JA</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Abrogating mitochondrial dynamics in mouse hearts accelerates mitochondrial senescence</article-title><source>Cell Metabolism</source><volume>26</volume><fpage>872</fpage><lpage>883</lpage><pub-id pub-id-type="doi">10.1016/j.cmet.2017.09.023</pub-id><pub-id pub-id-type="pmid">29107503</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steinberg</surname><given-names>S</given-names></name><name><surname>Stefansson</surname><given-names>H</given-names></name><name><surname>Jonsson</surname><given-names>T</given-names></name><name><surname>Johannsdottir</surname><given-names>H</given-names></name><name><surname>Ingason</surname><given-names>A</given-names></name><name><surname>Helgason</surname><given-names>H</given-names></name><name><surname>Sulem</surname><given-names>P</given-names></name><name><surname>Magnusson</surname><given-names>OT</given-names></name><name><surname>Gudjonsson</surname><given-names>SA</given-names></name><name><surname>Unnsteinsdottir</surname><given-names>U</given-names></name><name><surname>Kong</surname><given-names>A</given-names></name><name><surname>Helisalmi</surname><given-names>S</given-names></name><name><surname>Soininen</surname><given-names>H</given-names></name><name><surname>Lah</surname><given-names>JJ</given-names></name><collab>DemGene</collab><name><surname>Aarsland</surname><given-names>D</given-names></name><name><surname>Fladby</surname><given-names>T</given-names></name><name><surname>Ulstein</surname><given-names>ID</given-names></name><name><surname>Djurovic</surname><given-names>S</given-names></name><name><surname>Sando</surname><given-names>SB</given-names></name><name><surname>White</surname><given-names>LR</given-names></name><name><surname>Knudsen</surname><given-names>GP</given-names></name><name><surname>Westlye</surname><given-names>LT</given-names></name><name><surname>Selbæk</surname><given-names>G</given-names></name><name><surname>Giegling</surname><given-names>I</given-names></name><name><surname>Hampel</surname><given-names>H</given-names></name><name><surname>Hiltunen</surname><given-names>M</given-names></name><name><surname>Levey</surname><given-names>AI</given-names></name><name><surname>Andreassen</surname><given-names>OA</given-names></name><name><surname>Rujescu</surname><given-names>D</given-names></name><name><surname>Jonsson</surname><given-names>PV</given-names></name><name><surname>Bjornsson</surname><given-names>S</given-names></name><name><surname>Snaedal</surname><given-names>J</given-names></name><name><surname>Stefansson</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Loss-of-function variants in ABCA7 confer risk of Alzheimer’s disease</article-title><source>Nature Genetics</source><volume>47</volume><fpage>445</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1038/ng.3246</pub-id><pub-id pub-id-type="pmid">25807283</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stuppia</surname><given-names>G</given-names></name><name><surname>Rizzo</surname><given-names>F</given-names></name><name><surname>Riboldi</surname><given-names>G</given-names></name><name><surname>Del Bo</surname><given-names>R</given-names></name><name><surname>Nizzardo</surname><given-names>M</given-names></name><name><surname>Simone</surname><given-names>C</given-names></name><name><surname>Comi</surname><given-names>GP</given-names></name><name><surname>Bresolin</surname><given-names>N</given-names></name><name><surname>Corti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>MFN2-related neuropathies: Clinical features, molecular pathogenesis and therapeutic perspectives</article-title><source>Journal of the Neurological Sciences</source><volume>356</volume><fpage>7</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1016/j.jns.2015.05.033</pub-id><pub-id pub-id-type="pmid">26143526</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trachtenberg</surname><given-names>BH</given-names></name><name><surname>Jimenez</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>AA</given-names></name><name><surname>Kransdorf</surname><given-names>E</given-names></name><name><surname>Owens</surname><given-names>A</given-names></name><name><surname>Fishbein</surname><given-names>DP</given-names></name><name><surname>Jordan</surname><given-names>E</given-names></name><name><surname>Kinnamon</surname><given-names>DD</given-names></name><name><surname>Mead</surname><given-names>JO</given-names></name><name><surname>Huggins</surname><given-names>GS</given-names></name><name><surname>Hershberger</surname><given-names>RE</given-names></name><collab>DCM Precision Medicine Study of the DCM Consortium</collab></person-group><year iso-8601-date="2022">2022</year><article-title>TTR variants in patients with dilated cardiomyopathy: An investigation of the DCM Precision Medicine Study</article-title><source>Genetics in Medicine</source><volume>24</volume><fpage>1495</fpage><lpage>1502</lpage><pub-id pub-id-type="doi">10.1016/j.gim.2022.03.011</pub-id><pub-id pub-id-type="pmid">35438637</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallace</surname><given-names>KB</given-names></name><name><surname>Sardão</surname><given-names>VA</given-names></name><name><surname>Oliveira</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial determinants of doxorubicin-induced cardiomyopathy</article-title><source>Circulation Research</source><volume>126</volume><fpage>926</fpage><lpage>941</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.314681</pub-id><pub-id pub-id-type="pmid">32213135</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Jin</surname><given-names>S</given-names></name><name><surname>Ding</surname><given-names>WX</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>New methods for monitoring mitochondrial biogenesis and mitophagy in vitro and in vivo</article-title><source>Experimental Biology and Medicine</source><volume>242</volume><fpage>781</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1177/1535370216688802</pub-id><pub-id pub-id-type="pmid">28093935</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>W</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>An</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cai</surname><given-names>W</given-names></name><name><surname>Bai</surname><given-names>Y</given-names></name><name><surname>Zhan</surname><given-names>Q</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name><name><surname>Zeng</surname><given-names>Q</given-names></name><name><surname>Ren</surname><given-names>H</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mitofusin 2 participates in mitophagy and mitochondrial fusion against angiotensin ii-induced cardiomyocyte injury</article-title><source>Frontiers in Physiology</source><volume>10</volume><elocation-id>411</elocation-id><pub-id pub-id-type="doi">10.3389/fphys.2019.00411</pub-id><pub-id pub-id-type="pmid">31024347</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Carmona</surname><given-names>S</given-names></name><name><surname>Muhammad</surname><given-names>A</given-names></name><name><surname>Bell</surname><given-names>S</given-names></name><name><surname>Landeros</surname><given-names>J</given-names></name><name><surname>Vazquez</surname><given-names>M</given-names></name><name><surname>Ho</surname><given-names>R</given-names></name><name><surname>Franco</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>B</given-names></name><name><surname>Dorn</surname><given-names>GW</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Lutz</surname><given-names>CM</given-names></name><name><surname>Baloh</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Restoring mitofusin balance prevents axonal degeneration in a Charcot-Marie-Tooth type 2A model</article-title><source>The Journal of Clinical Investigation</source><volume>131</volume><elocation-id>e147307</elocation-id><pub-id pub-id-type="doi">10.1172/JCI147307</pub-id><pub-id pub-id-type="pmid">33463548</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Züchner</surname><given-names>S</given-names></name><name><surname>Mersiyanova</surname><given-names>IV</given-names></name><name><surname>Muglia</surname><given-names>M</given-names></name><name><surname>Bissar-Tadmouri</surname><given-names>N</given-names></name><name><surname>Rochelle</surname><given-names>J</given-names></name><name><surname>Dadali</surname><given-names>EL</given-names></name><name><surname>Zappia</surname><given-names>M</given-names></name><name><surname>Nelis</surname><given-names>E</given-names></name><name><surname>Patitucci</surname><given-names>A</given-names></name><name><surname>Senderek</surname><given-names>J</given-names></name><name><surname>Parman</surname><given-names>Y</given-names></name><name><surname>Evgrafov</surname><given-names>O</given-names></name><name><surname>Jonghe</surname><given-names>PD</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Tsuji</surname><given-names>S</given-names></name><name><surname>Pericak-Vance</surname><given-names>MA</given-names></name><name><surname>Quattrone</surname><given-names>A</given-names></name><name><surname>Battaloglu</surname><given-names>E</given-names></name><name><surname>Polyakov</surname><given-names>AV</given-names></name><name><surname>Timmerman</surname><given-names>V</given-names></name><name><surname>Schröder</surname><given-names>JM</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A</article-title><source>Nature Genetics</source><volume>36</volume><fpage>449</fpage><lpage>451</lpage><pub-id pub-id-type="doi">10.1038/ng1341</pub-id><pub-id pub-id-type="pmid">15064763</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Züchner</surname><given-names>S</given-names></name><name><surname>De Jonghe</surname><given-names>P</given-names></name><name><surname>Jordanova</surname><given-names>A</given-names></name><name><surname>Claeys</surname><given-names>KG</given-names></name><name><surname>Guergueltcheva</surname><given-names>V</given-names></name><name><surname>Cherninkova</surname><given-names>S</given-names></name><name><surname>Hamilton</surname><given-names>SR</given-names></name><name><surname>Van Stavern</surname><given-names>G</given-names></name><name><surname>Krajewski</surname><given-names>KM</given-names></name><name><surname>Stajich</surname><given-names>J</given-names></name><name><surname>Tournev</surname><given-names>I</given-names></name><name><surname>Verhoeven</surname><given-names>K</given-names></name><name><surname>Langerhorst</surname><given-names>CT</given-names></name><name><surname>de Visser</surname><given-names>M</given-names></name><name><surname>Baas</surname><given-names>F</given-names></name><name><surname>Bird</surname><given-names>T</given-names></name><name><surname>Timmerman</surname><given-names>V</given-names></name><name><surname>Shy</surname><given-names>M</given-names></name><name><surname>Vance</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2</article-title><source>Annals of Neurology</source><volume>59</volume><fpage>276</fpage><lpage>281</lpage><pub-id pub-id-type="doi">10.1002/ana.20797</pub-id><pub-id pub-id-type="pmid">16437557</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84235.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chacinska</surname><given-names>Agnieszka</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01dr6c206</institution-id><institution>IMol Polish Academy of Sciences</institution></institution-wrap><country>Poland</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2022.11.22.517462" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.22.517462"/></front-stub><body><p>The study presents a valuable finding on the link between mitofusin function (MFN2) and Parkin-mediated mitophagy, and that the combination of mitophagy and mitochondrial fusion defects is the basis of cardiomyopathy. The data based on the in vivo models are compelling and provide clinically relevant associations. This finding is important for understanding mitochondrial defects as a basis of heart pathologies.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84235.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Chacinska</surname><given-names>Agnieszka</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01dr6c206</institution-id><institution>IMol Polish Academy of Sciences</institution></institution-wrap><country>Poland</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2022.11.22.517462">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2022.11.22.517462v1">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;A human mitofusin 2 mutation causes mitophagic cardiomyopathy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 2 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Martin Pollak as the Senior Editor. The reviewers have opted to remain anonymous.</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>The reviewers find the paper valuable however they raised a number of points, which in our opinion are necessary to fully justify the conclusions. The most important part of revisions should provide additional evidence for a link between the mitofusin mutation R400Q and cardiomyopathy. Furthermore, additional support is needed to substantiate the defect in Parkin recruitment and mitophagy. The recommendations to the authors contain the requested or suggested experiments that would strengthen the findings and the importance of this nice study.</p><p><italic>Reviewer #1 (Recommendations for the authors):</italic></p><p>1. Replicate the association between MFN2 R400Q and cardiomyopathy using another dataset, e.g., the UK Biobank (which has a cohort design) or an independent dataset that has well matched cases and controls.</p><p>2. Report clearly the source and characteristics of the cases used in the association study described in Table 1.</p><p>3. In support of the claims in Figure 2A, assess Parkin recruitment to mitochondria in addition to the puncta formation. Assess downstream Parkin function such as a mitophagy assay would strengthen this assertion. If this can be done in a flow cytometry based assay (e.g., with mt-Keima) that requires less interpretation on the part of the experimenter that would increase confidence in the reproducibility of this line of experimentation.</p><p>4. Relatedly, the argument would be strengthened by in vivo data demonstrating decreased heart mitophagy in the KI mouse model (e.g., by injected of an AAV fluorescent mitophagy reporter such as mt-Keima, mito-GR, or mito-SRAI).</p><p>5. The authors should assess for cardiomyopathy in the heterozygous MFN2 R400Q mice or revise their claim that these data with knockin mouse support the idea that dominant mutations in MFN2 cause cardiomyopathy.</p><p>6. Page 9. Two CMT2A mutations are tested to establish a double disassociation between CMT2A-causing mutations and the R400Q variant which is proposed to be cardiomyopathy causing. However, the CMT2A mutations chosen all affect GTPase activity. What about CMT2A mutations that do not disrupt GTPase activity? Do they similarly not affect MFN2 conformational change in the FRET assay and Parkin recruitment.</p><p>7. In Figure 4H, couldn't these results mean that MFN2 R400Q is loss of function but not dominant negative whereas the other GTPase variants tested are dominant negative. What if these experiments are repeated in a cell line that lacks MFN2?</p><p>8. Line 22, page 3. I recommend adding a comma before &quot;we.&quot;</p><p>9. Line 37, page 3. &quot;[M]ean allele frequency&quot; should be &quot;minor allele frequency&quot; as the authors previously states in line 23, page 3.</p><p>10. Line 34, page 6. I recommend deleting &quot;Note-.&quot;</p><p>11. Figure 1F. Please describe how percentage of depolarized mitos were determined in the method section.</p><p>12. Figure 3C. Please describe what the numbers in bars indicate in the figure legend.</p><p>13. Figure 3D. Specify genotypes of the fetus.</p><p>14. Figure 5. I recommend mutating T111E and S442E on the adenoviral MFN2 R400Q construct to see if the mitophagy suppression can be rescued.</p><p>15. Missense mutations have been reported throughout different regions of MFN2 to cause CMT2A, including the same region as R400Q (eg. R400P and R397P). The argument that the unique combination of mitochondrial defects is the mechanistic basis for tissue specificity can be strengthened if a CMT mutation in the same region can be shown to lead to different mitochondrial defects and another mutation that affects confirmational malleability also leads to cardiac-specific disease.</p><p><italic>Reviewer #2 (Recommendations for the authors):</italic></p><p>1. The authors separated their Mfn2 Q400 homozygous knock-in mice into Mfn2 Q/Q400n (normal) and Mfn2 Q/Q400a (abnormal) and the data look interesting. However, they didn't clarify the criteria in distinguishing between two subtypes (by H&amp;E staining results from Figure 3E maybe?). How about Mitofusin 2 expression level as well as the GTPase activity in these two subtypes? And based on their observation in Figure 3C, is Mfn2 Q/Q400n viable after P35 but not Mfn2 Q/Q400a? Moreover, what's the rationale of separating Mfn2 Q/Q400n and Mfn2 Q/Q400a in Figure 4- Supplemental 1 but combine them in Figure 4-Supplemental 2? In addition, for Figure 4D-G, are the data from Mfn2 Q/Q400a or Mfn2 Q/Q400n mice? This is probably the single most troubling aspect of the current study that needed to be rigorously dealt with.</p><p>2. Mechanistically, the authors showed that the Mfn2 Q400 mutant impaired mitophagy with decreased Parkin recruitment in vitro. However, the authors failed to address how this impairment in Parkin-mediated mitophagy results in perinatal cardiomyopathy in vivo. Indeed, this groups previous publication showed Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation and inhibition of Parkin-mediated mitophagy caused lethal cardiomyopathy (doi: 10.1126/science.aad2459). However, how the current mutation in MFN2 relates is unclear, and direct evidence is needed to support the relevance of this manuscript and the mechanistic importance as to how the Q400 mutation is causing earl cardiomyopathy.</p><p>3. Mfn2 needs to be phosphorylated to serve as the Parkin receptor. While the authors showed no change in Mfn2 protein level in their mutants, have the authors examined Mfn2 phosphorylation level? This would seem to be critical.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.84235.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>The reviewers find the paper valuable however they raised a number of points, which in our opinion are necessary to fully justify the conclusions. The most important part of revisions should provide additional evidence for a link between the mitofusin mutation R400Q and cardiomyopathy.</p></disp-quote><p>We thank the editors and reviewers for their detailed comments. We have performed a large amount of additional experimentation to strengthen the mechanistic link between MFN2 R400Q and cardiomyopathy: 1. We demonstrate that defective MFN2-mediated Parkin recruitment caused by the R400Q mutation evokes mitophagic dysfunction both in vitro in cultured H9c2 cardiomyoblasts and in vivo in Q/Q400 knock-in mice dosed with doxorubicin.</p><disp-quote content-type="editor-comment"><p>Furthermore additional support is needed to substantiate the defect in Parkin recruitment and mitophagy.</p></disp-quote><p>Although we wonder if the mito-QC data included in the original submission may have been overlooked, we now additionally report that: 1. MFN2 R400Q, but not CMT2A-associated MFN2 T105M or M376A/V, impairs FCCP-stimulated mitochondrial Parkin recruitment, autophagosomal engulfment of mitochondria, and mitochondrial delivery to lysosomes in H9c2 cardiomyoblasts; 2. MFN2 R400Q reduces mitochondrial Parkin aggregation and mitolysosome formation in H9c2 cardiomyoblasts treated with doxorubicin; and 3. MFN2 R400Q knock-in mice exhibit both a reduced myocardial mitophagy response to doxorubicin and increased susceptibility to doxorubicin-induced cardiomyopathy.</p><disp-quote content-type="editor-comment"><p>The recommendations to the authors contain the requested or suggested experiments that would strengthen the findings and the importance of this nice study.</p></disp-quote><p>As detailed in our responses to the reviewers, we’ve tried to address every concern. As you will appreciate, the manuscript has undergone major changes. While we have endeavored to retain all data from the original submission, to more effectively delineate and convey to readers the different properties of various disease-associated MFN2 mutations as specified by R1 in the 15<sup>th</sup> Recommendation to Authors, the revised manuscript has been re-structured as a series of side-by-side comparisons between cardiomyopathy-associated MFN2 R400Q and two CMT2A-associated MFN2 mutations, MFN2 T105M in the GTPase domain and MFN2 M376A/V, in the HR1 domain. These specific comparisons are reported every scientific level: biophysical studies of protein conformation switching; enzymatic studies of catalytic GTPase activity; live-cell studies of mitochondrial fusion, polarization, motility and respiration in multiple cell types; mitophagy studies of mitochondrial Parkin localization and mitolysosome formation, and in vivo studies of mutant knock-in mice, including <italic>data from two new (Mfn2 T105M and M376V) mouse KI models</italic>. Previous data on artificial MFN2 mutants have been moved to the figure supplements. We believe that these changes have not only strengthened our conclusions, but increased the scientific and clinical impact of our findings.</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Recommendations for the authors):</p><p>1. Replicate the association between MFN2 R400Q and cardiomyopathy using another dataset, e.g., the UK Biobank (which has a cohort design) or an independent dataset that has well matched cases and controls.</p></disp-quote><p>We have added genotyping data from the matched non-affected control population (n=861) of the Cincinnati Heart study to our analyses (page 4). The conclusions did not change.</p><disp-quote content-type="editor-comment"><p>2. Report clearly the source and characteristics of the cases used in the association study described in Table 1.</p></disp-quote><p>The details of our study cohorts were inadvertently omitted during manuscript preparation. As now reported on pages 3 and 4, the Cincinnati Heart Study is a case-control study consisting of 1,745 cardiomyopathy (1,117 Caucasian and 628 African American) subjects and 861 non-affected controls (625 Caucasian and 236 African American) (Liggett et al. <italic>Nat Med</italic> 2008; Matkovich et al. <italic>JCI</italic> 2010; Cappola et al. <italic>PNAS</italic> 2011). The Houston hypertrophic cardiomyopathy cohort (which has been screened by linkage analysis, candidate gene sequencing or clinical genetic testing) included 286 subjects (240 Caucasians and 46 African Americans) (Osio A et al. <italic>Circ Res</italic> 2007; Li L et al. <italic>Circ Res</italic> 2017).</p><disp-quote content-type="editor-comment"><p>3. In support of the claims in Figure 2A, assess Parkin recruitment to mitochondria in addition to the puncta formation. Assess downstream Parkin function such as a mitophagy assay would strengthen this assertion. If this can be done in a flow cytometry based assay (e.g., with mt-Keima) that requires less interpretation on the part of the experimenter that would increase confidence in the reproducibility of this line of experimentation.</p></disp-quote><p>The reviewer may have overlooked the studies reported in original Figure 5, in which Parkin localization to cultured cardiomyoblast mitochondria is linked both to mitochondrial autophagy (LC3-mitochondria overlay) and to formation of mito-lysosomes (MitoQC staining). These results have been retained and expanded to include MFN2 M376A in Figure 6 B-E and Figure 6 Figure Supplement 1 of the revised manuscript. Additionally, selective impairment of Parkin recruitment to mitochondria was shown in mitofusin null MEFs in current Figure 3C and Figure 3 Figure Supplement 1, panels B and C.</p><p>The in vitro and in vivo doxorubicin studies performed for the revision further strengthen the mechanistic link between cardiomyocyte toxicity, reduced parkin recruitment and impaired mitophagy in MFN2 R400Q expressing cardiac cells: MFN2 R400Q-amplified doxorubicin-induced H9c2 cell death is associated with reduced Parkin aggregation and mitolysosome formation in vitro, and the exaggerated doxorubicin-induced cardiomyopathic response in MFN2 Q/Q400 mice was associated with reduced cardiomyocyte mitophagy in vivo, measured with adenoviral Mito-QC (new Figure 7).</p><p>The LC3-mitochondrial overlay and MitoQC green-red shift data originally provided, now in Figure 6B-C and Figure 6 Figure Supplement 1. Parkin recruitment to/aggregation at mitochondria is now specifically demonstrated in Figure 3 Figure Supplement 1B, as well as extensively in the published literature.</p><disp-quote content-type="editor-comment"><p>4. Relatedly, the argument would be strengthened by in vivo data demonstrating decreased heart mitophagy in the KI mouse model (e.g., by injected of an AAV fluorescent mitophagy reporter such as mt-Keima, mito-GR, or mito-SRAI).</p></disp-quote><p>We are intrigued that in the previous comment the reviewer warns that murine phenocopies are not 100% predictive of human disease, and in the next sentence he/she requests that we show that the gene dose-phenotype response is the same in mice and humans. And, we again wish to note that we never argued that MFN2 R400Q “causes a dominant cardiomyopathy in humans.” Nevertheless, we understand the underlying concerns and in the revised manuscript we present data from new doxorubicin challenge experiments comparing cardiomyopathy development and myocardial mitophagy in WT, heterozygous, and surviving (Q/Q400n) homozygous Mfn2 R400Q KI mice (new Figure 7, panels E-G). Homozygous, but not heterozygous, R400Q mice exhibited an amplified cardiomyopathic response (greater LV dilatation, reduced LV ejection performance, exaggerated LV hypertrophy) and an impaired myocardial mitophagic response to doxorubicin. These in vivo data recapitulate new in vitro results in H9c2 rat cardiomyoblasts expressing MFN2 R400Q, which exhibited enhanced cytotoxicity (cell death and TUNEL labelling) to doxorubicin associated with reduced reactive mitophagy (Parkin aggregation and mitolysosome formation) (new Figure 7, panels A-D). Thus, under the limited conditions we have explored to date we do not observe cardiomyopathy development in heterozygous Mfn2 R400Q KI mice. However, we have expanded the association between R400Q, mitophagy and cardiomyopathy thereby providing the desired additional support for our argument that it can be a cardiomyopathy risk modifier.</p><disp-quote content-type="editor-comment"><p>5. The authors should assess for cardiomyopathy in the heterozygous MFN2 R400Q mice or revise their claim that these data with knockin mouse support the idea that dominant mutations in MFN2 cause cardiomyopathy.</p></disp-quote><p>We have performed the requested experiment, we do not see cardiomyopathy in heterozygous R400Q mice, and we have not revised the claims we actually made in the original manuscript:</p><disp-quote content-type="editor-comment"><p>6. Page 9. Two CMT2A mutations are tested to establish a double disassociation between CMT2A-causing mutations and the R400Q variant which is proposed to be cardiomyopathy causing. However, the CMT2A mutations chosen all affect GTPase activity. What about CMT2A mutations that do not disrupt GTPase activity? Do they similarly not affect MFN2 conformational change in the FRET assay and Parkin recruitment.</p></disp-quote><p>MFN2 M376A/V data have been added throughout to address this concern. The catalog of MFN2 mutations used clearly dissociates GTPase activity, conformational change, and Parkin recruitment. Please see data in Figures 1-3 and 6 and their accompanying supplements; these data are summarized in <xref ref-type="table" rid="sa2table1">Author response table 1</xref>.</p><table-wrap id="sa2table1" position="float"><label>Author response table 1.</label><table frame="hsides" rules="groups"><thead><tr><th>MFN2 mutant</th><th>GTPase activity</th><th>Conformation change</th><th>Fusion</th><th>Polarization</th><th>Respiration</th><th>Mitophagy</th><th>Motility</th><th>KI phenotype</th></tr></thead><tbody><tr><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/><td align="left" valign="top"/></tr><tr><td align="left" valign="top">T105M</td><td align="left" valign="top">Inactive</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">CMT2A (het)<break/>Emb let (homo)</td></tr><tr><td align="left" valign="top">M376A/V</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Impaired</td><td align="left" valign="top">Functional null</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Functional null</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Normal</td></tr><tr><td align="left" valign="top">R400Q</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Impaired</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Functional null</td><td align="left" valign="top">Dominant suppressor</td><td align="left" valign="top">Normal</td><td align="left" valign="top">Cardiomyopathy (homo)</td></tr></tbody></table></table-wrap><disp-quote content-type="editor-comment"><p>7. In Figure 4H, couldn't these results mean that MFN2 R400Q is loss of function but not dominant negative whereas the other GTPase variants tested are dominant negative. What if these experiments are repeated in a cell line that lacks MFN2?</p></disp-quote><p>Our results in the original submission, which are retained in Figures 1D and 1E and Figure 1 Figure Supplement 1 of the revision, exclude the possibility that R400Q is a functional null mutant for, but not a dominant suppressor of, mitochondrial fusion. We have added additional data for M376A in the revision, but the original results are retained in the main figure panels and a new supplemental figure.</p><p>Figure 1D reports results of mitochondrial elongation studies (the morphological surrogate for mitochondrial fusion) performed in Mfn1/Mfn2 double knock-out (DKO) MEFs. The baseline mitochondrial aspect ratio in DKO cells infected with control (b-gal containing) virus is ~2 (white bar), and increases to ~6 (i.e. ~normal) by forced expression of WT MFN2 (black bar). By contrast, aspect ratio in DKO MEFs expressing MFN2 mutants T105M (green bar), M376A and R400Q (red bars in main figure), R94Q and K109A (green bars in the supplemental figure) is only 3-4. For these results the reviewer’s and our interpretation agree: all of the MFN2 mutants studied are non-functional as mitochondrial fusion proteins.</p><p>Importantly, Figure 1E (left panel) reports the results of parallel mitochondrial elongation studies performed in WT MEFs, i.e. in the presence of normal endogenous Mfn1 and Mfn2. Here, baseline mitochondrial aspect ratio is already normal (~6, white bar), and increases modestly to ~8 when WT MFN2 is expressed (black bar). By comparison, aspect ratio is reduced below baseline by expression of four of the five MFN2 mutants, including MFN2 R400Q (main figure and accompanying supplemental figure; green and red bars). Only MFN2 M376A failed to suppress mitochondrial fusion promoted by endogenous Mfns 1 and 2. Thus, MFN2 R400Q dominantly suppresses mitochondrial fusion. We have stressed this point in the text on page 5, first complete paragraph.</p><disp-quote content-type="editor-comment"><p>8. Line 22, page 3. I recommend adding a comma before &quot;we.&quot;</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>9. Line 37, page 3. &quot;[M]ean allele frequency&quot; should be &quot;minor allele frequency&quot; as the authors previously states in line 23, page 3.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>10. Line 34, page 6. I recommend deleting &quot;(Note-.&quot;</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>11. Figure 1F. Please describe how percentage of depolarized mitos were determined in the method section.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>12. Figure 3C. Please describe what the numbers in bars indicate in the figure legend.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>13. Figure 3D. Specify genotypes of the fetus.</p></disp-quote><p>Done.</p><disp-quote content-type="editor-comment"><p>14. Figure 5. I recommend mutating T111E and S442E on the adenoviral MFN2 R400Q construct to see if the mitophagy suppression can be rescued.</p></disp-quote><p>This is an interesting idea that we are exploring on a much larger scale by comparing the consequences of multiple MFN2 genetic mutations vs a variety of normal post-translational modifications in MFN regulation/dysregulation. Results describing functional interplay between genetic defect and post-translational modification, including many complementary experiments, will be published separately.</p><disp-quote content-type="editor-comment"><p>15. Missense mutations have been reported throughout different regions of MFN2 to cause CMT2A, including the same region as R400Q (eg. R400P and R397P). The argument that the unique combination of mitochondrial defects is the mechanistic basis for tissue specificity can be strengthened if a CMT mutation in the same region can be shown to lead to different mitochondrial defects and another mutation that affects confirmational malleability also leads to cardiac-specific disease.</p></disp-quote><p>This seemingly simple final request required us to perform the entire spectrum of comparative analyses between MFN2 R400Q vs multiple CMT2A-linked mutations in different MFN2 domains, including using MFN2 mutant KI mouse models that did not exist. The scope of this “recommendation” is breathtaking and, in the experience of the senior author, without precedent. Nevertheless, we have complied.</p><p>After careful consideration we selected CMT2A mutations different than those suggested by the reviewer because: 1. Proline substitutions provoke major structural changes in helical supercoils; 2. The suggested MFN2 mutants are vanishingly rare (perhaps single individuals or families); and 3. Neither of the suggested mutations are validated in CMT2A. Rather, we selected the prototypical MFN2 T105M GTPase domain and M376A/V HR1 mutations, each of which have been described multiple times in CMT2A patients. The revised manuscript has been restructured throughout to compare MFN2 R400Q to T105M and M376A/V.</p><p>The new results further support our original conclusion. To be clear however, the conclusion is not that a problem with conformational malleability confers cardiac disease as indicated by the reviewer, but that a problem with Parkin recruitment and downstream mitophagy evokes cardiomyopathy. Data in the revised manuscript, including analyses of new MFN2 T105M and M376V CRISPR/Cas9 KI mouse lines created for this purpose, strongly support this concept. Please see <xref ref-type="table" rid="sa2table1">Author response table 1</xref>.</p><disp-quote content-type="editor-comment"><p>Reviewer #2 (Recommendations for the authors):</p><p>1. The authors separated their Mfn2 Q400 homozygous knock-in mice into Mfn2 Q/Q400n (normal) and Mfn2 Q/Q400a (abnormal) and the data look interesting. However, they didn't clarify the criteria in distinguishing between two subtypes (by H&amp;E staining results from Figure 3E maybe?). How about Mitofusin 2 expression level as well as the GTPase activity in these two subtypes? And based on their observation in Figure 3C, is Mfn2 Q/Q400n viable after P35 but not Mfn2 Q/Q400a? Moreover, what's the rationale of separating Mfn2 Q/Q400n and Mfn2 Q/Q400a in Figure 4- Supplemental 1 but combine them in Figure 4-Supplemental 2? In addition, for Figure 4D-G, are the data from Mfn2 Q/Q400a or Mfn2 Q/Q400n mice? This is probably the single most troubling aspect of the current study that needed to be rigorously dealt with.</p><p>2. Mechanistically, the authors showed that the Mfn2 Q400 mutant impaired mitophagy with decreased Parkin recruitment in vitro. However, the authors failed to address how this impairment in Parkin-mediated mitophagy results in perinatal cardiomyopathy in vivo. Indeed, this groups previous publication showed Parkin-mediated mitophagy directs perinatal cardiac metabolic maturation and inhibition of Parkin-mediated mitophagy caused lethal cardiomyopathy (doi: 10.1126/science.aad2459). However, how the current mutation in MFN2 relates is unclear, and direct evidence is needed to support the relevance of this manuscript and the mechanistic importance as to how the Q400 mutation is causing earl cardiomyopathy.</p></disp-quote><p>If I understand, the reviewer is asking us to solidify the connection between the in vitro mitophagy defect of MFN2 Q400 and the in vivo cardiomyopathy in Mfn2 Q400 KI mice. This is similar to a major concern expressed by R1 who proposed that impaired mitochondrial fusion could be sufficient to explain the in vivo phenotype. We reasoned that the most rigorous way to do this was to extend our previous comparative in vitro analysis of a spectrum of MFN2 mutations to the in vivo mouse. The original submission included in vitro comparisons of MFN2 R400Q to the natural CMT2A MFN2 mutants R94Q and T105M (both GTPase domain) and to Mfn2 K109A that was laboratory engineered specifically to be GTPase defective. All of these data have been retained in revision, but R94Q and K109A results have been moved to figure supplements. We have added results for MFN2 M376A/V, a putative CMT2A mutant locus that like MFN2 R400Q is located within the HR1 domain. As noted in the table embedded in our responses to R1, T105M, M376A/V and R400Q represent natural MFN2 mutants that cover the entire spectrum of dysfunction.</p><p>By comparing the biochemical/biophysical, cellular and in vivo defects across all three mutants it was possible to exclude impaired fusion as the cause of observed cardiomyopathy (because T105M and M376A/V have similar fusogenic defects). Likewise, it is not possible that defective conformational shifting explains the cardiomyopathy (because M376A/V has the same impaired shape shifting as R400Q). Indeed, the only unique feature of R400Q is defective Parkin recruitment and mitophagy, and the only functional characteristic unique to R400Q that causes myocardial disease in KI mice relates to Parkin-mediated mitophagy. By the same reasoning, the only functional characteristic unique to T105M is mitochondrial dysmotility, which as we and others have described is mechanistically linked to neuropathy.</p><p>Regarding the comparison made by the reviewer with our previous work expressing mitophagy-defective MFN2 AA (T111, S442 engineered to non-phosphorylated Ala [A]) or MFN2 EE (same 2 amino acids engineered to Glu [E]): MFN2 AA has normal fusion but cannot bind Parkin (like R400Q) and when transgenically expressed from birth caused perinatal myopathy (like R400Q). (Side-by-side comparisons of MFN2 R400Q with MFN2 AA and EE in Figure 2 of the original submission have been moved to the Figure 3 Figure Supplement 1 to accommodate T105M and M376A/V data.) As noted in the manuscript (pg 9), the distinct metabolic and transcriptional signatures of the cardiomyopathy in Mfn2 AA mice are similar to those for the current R400Q mice. These similarities are consistent with the notion that interfering with cardiomyocyte mitophagy by interrupting MFN2-Parkin interactions cause mitophagic cardiomyopathy due to metabolic mismatch. We’d like to emphasize that the Gong et al. Science paper used cardiac-specific transgenic overexpression of an engineered Mfn2 from birth, whereas the current manuscript is a knock-in mouse wherein the (natural) Mfn2 R400Q mutant is expressed everywhere, but specifically impacted the heart.</p><p>Finally, we have now performed in vitro and in vivo studies using doxorubicin to stimulate compensatory cardiomyocyte mitophagy, which was suppressed by MFN2 Q400. The consequence in vitro and in vivo was increased sensitivity of MFN2 Q400 expressing cardiac cells to doxorubicin. These data are reported in a new manuscript section on pages 9 and 10, and new Figure 7. Together, we believe we’ve made a strong case that mitophagy underlies the cardiomyopathy provoked by MFN2 R400Q.</p><disp-quote content-type="editor-comment"><p>3. Mfn2 needs to be phosphorylated to serve as the Parkin receptor. While the authors showed no change in Mfn2 protein level in their mutants, have the authors examined Mfn2 phosphorylation level? This would seem to be critical.</p></disp-quote><p>This is a good question, which relates to the important issue of how post-translational mechanisms might be induced to compensate for genetic variation. Because Mfn2 is a poly-phosphorylated protein substrate for multiple kinases we don’t believe that interpretable data will be forthcoming from general determinations of Mfn2 phosphorylation level like Phos-tag SDS PAGE that we used a decade ago (Dorn and Chen, Science 2013). Rather, we are pursuing this idea by individual and combinatorial mutagenesis of functionally-relevant MFN2 phosphorylation sites (see Li et al. Front Cell Dev Biol 2022) in the context of our panel of disease-linked MFN2 mutations. This is an ongoing and extensive project whose results will be published in their entirety when completed. We can say that we see no evidence for altered MFN2 Q400 phosphorylation in otherwise normal cardiac cells.</p></body></sub-article></article>